MK2-Deficient Mice Are Bradycardic and Display Delayed Hypertrophic Remodeling in Response to a Chronic Increase in Afterload

Matthieu Ruiz, PhD; Maya Khairallah, PhD; Dharmendra Dingar, PhD; George Vaniotis, PhD; Ramzi J. Khairallah, PhD; Benjamin Lauzier, PhD; Simon Thibault, BSc; Joëlle Trépanier, MSc; Yanfen Shi, MD; Annie Douillette, MSc; Bahira Hussein, MSc; Sherin Ali Nawaito, MD, MSc, PhD; Pramod Sahadevan, PhD; Albert Nguyen, PhD; Fatima Sahmi, PhD; Marc-Antoine Gillis, MSc; Martin G. Sirois, PhD; Matthias Gaestel, PhD; William C. Stanley, PhD; Céline Fiset, PhD; Jean-Claude Tardif, MD; Bruce G. Allen, PhD

BACKGROUND: Mitogen-activated protein kinase–activated protein kinase-2 (MK2) is a protein serine/threonine kinase activated by p38α/β. Herein, we examine the cardiac phenotype of pan MK2-null (MK2−/−) mice.

METHODS AND RESULTS: Survival curves for male MK2+/+ and MK2−/− mice did not differ (Mantel-Cox test, P=0.580). At 12 weeks of age, MK2−/− mice exhibited normal systolic function along with signs of possible early diastolic dysfunction; however, aging was not associated with an abnormal reduction in diastolic function. Both R-R interval and P-R segment durations were prolonged in MK2-deficient mice. However, heart rates normalized when isolated hearts were perfused ex vivo in working mode. Ca2+ transients evoked by field stimulation or caffeine were similar in ventricular myocytes from MK2+/+ and MK2−/− mice. MK2−/− mice had lower body temperature and an age-dependent reduction in body weight. mRNA levels of key metabolic genes, including Ppargc1a, Acadm, Lipe, and Ucp3, were increased in hearts from MK2−/− mice. For equivalent respiration rates, mitochondria from MK2−/− hearts showed a significant decrease in Ca2+ sensitivity to mitochondrial permeability transition pore opening. Eight weeks of pressure overload increased left ventricular mass in MK2+/+ and MK2−/− mice; however, after 2 weeks the increase was significant in MK2+/+ but not MK2−/− mice. Finally, the pressure overload–induced decrease in systolic function was attenuated in MK2−/− mice 2 weeks, but not 8 weeks, after constriction of the transverse aorta.

CONCLUSIONS: Collectively, these results implicate MK2 in (1) autonomic regulation of heart rate, (2) cardiac mitochondrial function, and (3) the early stages of myocardial remodeling in response to chronic pressure overload.

Key Words: bradycardia ■ cardiac remodeling ■ mitochondrial permeability transition pore ■ MK2 ■ p38 MAPK
hypothesis is seen as a compensatory phenomenon to normalize myocardial wall stress, when sustained, cardiac hypertrophy predisposes to sudden cardiac death, arrhythmia, and development of heart failure. Hence, understanding the basic signaling pathways involved in maintaining optimal cardiac function and their role in pressure overload--induced hypertrophy, as well as the associated contractile dysfunction, is necessary for the development of more effective means of prevention and treatment.

Several signaling pathways have been implicated in the transition from compensated hypertrophy to decompensated heart failure, including the mitogen-activated protein kinase (MAPK) pathway in which p38 MAPK plays a central role. Increased activation of p38 MAPK has been observed in both experimental and human heart failure. However, the pathological cardiac phenotype associated with p38 MAPK signaling is, to some extent, confusing. The literature contains seemingly contradictory reports indicating that p38 activation is both beneficial and detrimental during hypertrophy. Four isoforms of p38 MAPK (p38α, p38β, p38δ, and p38γ) are expressed in the heart, and p38α and p38β have been shown to be activated during pressure overload, and this activation correlates with ventricular hypertrophy. Similarly, p38γ and p38δ have been shown to mediate hypertrophy in response to angiotensin II infusion. Furthermore, in isolated cardiomyocytes, activation of p38 using either pharmacological or genetic approaches also suggests that p38 activation is prohypertrophic. The latter is reinforced by the attenuation of the hypertrophic response, evoked with phenylephrine or endothelin-1, using inhibitors of p38. In contrast, chronic inhibition of p38 signaling using dominant-negative p38α or p38β is associated with enhanced cardiac hypertrophy in response to pressure overload or following infusion with angiotensin II, isoproterenol, or phenylephrine. Similarly, cardiomyocyte-targeted deletion of p38α in mice did not impede hypertrophy in response to aortic banding, but increased both myocyte apoptosis and fibrosis while decreasing in cardiac contractility. In contrast, myocyte-targeted activation of p38α in adult mice induced hypertrophy, fibrosis, and mortality within 1 week.

Although there are divergent results, all convey a similar message, in which p38 MAPK signaling is essential for heart function and plays an important role in the pathogenesis of heart failure. However, the apparent opposing and divergent role for p38, as well as its numerous targets/substrates that are involved in a wide variety of cellular processes, makes it difficult to predict the impact of p38 inhibition in clinical trials. Moreover, none of the p38 inhibitors developed to date translated into safe and effective clinical strategies with low and acceptable toxicity because of their unwanted systemic side effects, which include hepatotoxicity, neurotoxicity, and cardiotoxicity. Hence, further research to better understand the role of p38 MAPK signaling in the healthy heart, especially with regards to its downstream targets, is essential to elucidate the potential therapeutic implications of targeting this signaling pathway. Over the past decade, many studies have focused on MK2, among other downstream p38 targets. Several reports suggested that targeting MK2 could lead to beneficial effects equivalent to those obtained when directly inhibiting p38 but with the additional advantage of lacking the side effects associated to p38 inhibitors and could therefore serve as a potential therapeutic target. Indeed, the side effects associated with p38 inhibitors...
Ruiz et al Role of MK2 in Cardiac Function

were recently attributed to the loss of feedback control of upstream TAB1/TAK1 signaling, which in turn leads to sustained activation of proinflammatory pathways.\textsuperscript{27,28} In contrast, this feedback control is maintained when using MK2 inhibitors, thereby preventing collateral activation of proinflammatory pathways.\textsuperscript{29} In addition, evidence suggests that MK2 may be an interesting target in other forms of cardiomyopathy.\textsuperscript{30} In fact, MK2 deficiency protects against ischemia-reperfusion injury.\textsuperscript{31} Streicher et al\textsuperscript{21} also reported that deleting MK2 in a conditional and cardiomyocyte-specific mouse model expressing constitutively active MAPK kinase 3 (MKK3) bE significantly reduces the MKK3bE-induced hypertrophy, improves contractile performance, and rescues lethality. In addition, pharmacological inhibition of MK2 reduces cardiac fibrosis and preserves cardiac function following myocardial infarction.\textsuperscript{32} Finally, we have recently shown that the absence of MK2 prevents diabetes mellitus–induced cardiac dysfunction and perturbations in lipid metabolism.\textsuperscript{30,33}

To date, few studies have examined the role of MK2 in either the healthy heart or in myocardial remodeling in response to a chronic increase in cardiac afterload. Therefore, using a previously described MK2-deficient mouse model,\textsuperscript{34} this study was undertaken to investigate (1) whether MK2 is involved in maintaining basal cardiac function and (2) whether MK2 plays a role in cardiac remodeling resulting from chronic pressure overload, in which case it would represent a potential therapeutic target.

METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval

All animal experiments were approved by the local ethics committee and performed according to the guidelines of the Canadian Council on Animal Care.

Animals

Twelve-week-old male wild-type (MK2\textsuperscript{+/+}) and MK2-deficient (MK2\textsuperscript{−/−}) littermate mice, on a mixed 129/Ola x C57BL/6J genetic background, were used. These mice have been described previously.\textsuperscript{34} MK2\textsuperscript{−/−} mice are viable, fertile, and show no behavioral or physiological defects.

In Vivo Cardiac Function

Radio Telemetry

Radio telemetry was used for continuous recordings of heart rate and ECG data in conscious unrestrained mice. MK2\textsuperscript{+/+} mice and age-matched MK2\textsuperscript{−/−} mice were instrumented, under isoflurane anesthesia (2.5% in O\textsubscript{2}, 0.5 L/min for induction and 1.5% for maintenance), with OpenHeart single-channel telemetry transmitters (Data Sciences International, Arden Hills, MN) as described previously.\textsuperscript{35} For analgesia, buprenorphine (0.05 mg/kg) was administered before and every 8 hours for 48 hours after surgery. Leads were placed in the conventional ECG lead II position with the positive transmitter lead located on the left anterior chest wall above the apex of the heart and the negative lead located on the right shoulder. Mice were provided with food and water ad libitum and maintained on a 12:12 hour day-night cycle. One week after surgery, data acquisition was initiated at a sampling frequency of 1 kHz and maintained for 48 hours. Recordings were analyzed with ECG Auto (version 2.8; EMKA Technologies, Paris, France). Briefly, the first 10 minutes of every 3-hour period was analyzed for the entire 48 hours of recording. A smoothing of 1 ms and notch filter of 60 Hz were used to reduce noise. Signals were averaged from 10 consecutive beats. ECG parameters were obtained through an automated signal detection using typical traces. The analyst was blinded as to genotype, and the mice shared the same library of typical traces. The QT interval was corrected for differences in R-R interval using the standard formula for mice (QTc=QT/(RR/100)\textsuperscript{1/2}).\textsuperscript{36} Heart rate variability was analyzed using Kubios HRV Standard (Version 3.0.0; Kubios, Kuopio, Finland) to fit an ellipse to a Poincaré plot (R−R\textsubscript{n} versus R−R\textsubscript{n+1}) of R-R interval data. Results were expressed as the ratio of the SD on the short axis (SD1) versus the SD on the long axis (SD2) of the ellipse. SD1 reflects short-term heart rate variability whereas SD2 reflects both short-term and long-term heart rate variability.\textsuperscript{37}

Surface ECGs

Surface ECG recordings were assessed on male MK2\textsuperscript{+/+} and MK2\textsuperscript{−/−} mice, under anesthesia with 2% isoflurane (100% O\textsubscript{2}, flow rate of 1 L/min), before and after intravenous injection of isoproterenol (0.1 μg/g) as previously described.\textsuperscript{38}

Transthoracic Echocardiography

Transthoracic echocardiographic imaging was performed on mice, sedated with isoflurane (2% in 100% O\textsubscript{2}, flow rate of 1 L/min), 1 day before constriction of the transverse aorta (TAC), for baseline evaluation, and 1 day before euthanasia. In the 8-week cohort, echocardiographic imaging was also performed 2 weeks after surgery. Examinations were carried out with a linear array i13L probe (10–14 MHz) using a
Vivid 7 Dimension ultrasound system (GE Healthcare, Horten, Norway). The operator was blinded to the genotype of the mice. All parameters and calculations related to left ventricular (LV) and right ventricular (RV) structure, LV and RV systolic function, LV and RV diastolic function, left atrium dimensions, and myocardial performance index were obtained as previously described.39–41

**Millar Catheterization**

Hemodynamic parameters were evaluated using a Mikro-Tip pressure transducer catheter (Millar Instruments, Houston, TX) in mice anesthetized with 2% isoflurane (100% O₂, flow rate of 1 L/min). Body temperature was monitored and maintained at 37°C using a heating pad. The catheter was inserted into the left ventricle through the carotid as previously reported.40 Recordings were analyzed using IOX software version 2.5.1.6 (EMKA Technologies, Sterling, VA).

**Transverse Aortic Constriction**

TAC was performed in 12-week-old male mice sedated with isoflurane gas as previously described.40 The surgeon was blinded as to the genotype of the mice. Sham animals underwent the identical surgical procedure, but the aorta was not constricted. Two or 8 weeks after surgery, mice were anesthetized with pentobarbital and euthanized, hearts removed, weighed, snap-frozen in liquid nitrogen-chilled 2-methyl butane, and stored at −80°C. Pentobarbital, rather than isoflurane, was always used before euthanaisa as isoflurane activates p38 MAP kinase in the mouse heart (data not shown).

**Ex Vivo Cardiac Function**

**Ex Vivo Working Heart Perfused in Semirecirculating Mode**

Hearts were isolated from fed mice and perfused under normoxic conditions for 30 minutes to evaluate basal function. To assess the impact of isoproterenol, hearts from a second group of mice were perfused under normoxic conditions for 20 minutes after which isoproterenol (10 nmol/L) was added to the buffer and perfusion continued for an additional 20 minutes. All perfusions were carried out at a fixed preload (15 mm Hg) and afterload (50 mm Hg, except following addition of isoproterenol [see below]), and using a semirecirculating modified Krebs-Henseleit buffer containing a mix of substrates and hormones as previously described42 in the absence (11 mmol/L glucose, 1.5 mmol/L lactate, 0.2 mmol/L pyruvate, 50 mmol/L carnitine, 0.8 nmol/L insulin, and 5 nmol/L epinephrine) or presence of palmitate (11 mmol/L glucose, 1.5 mmol/L lactate, 0.2 mmol/L pyruvate, and 0.7 mmol/L palmitate bound to 3% dialyzed albumin, 50 mmol/L carnitine, 0.8 nmol/L insulin, and 5 nmol/L epinephrine). During perfusion in the presence of isoproterenol (10 nmol/L) the afterload was increased to 60 mm Hg. Functional parameters were monitored throughout the perfusion (iox2 data acquisition software, EMKA Technologies): Data shown were acquired during the final 5 minutes of each perfusion.

**In Vitro Analyses on Isolated Ventricular Myocytes or Mitochondria**

**Ca²⁺ Transients and Caffeine-Induced Ca²⁺ Transients**

Ca²⁺ transients and sarcoplasmic reticulum Ca²⁺ content were assessed in cardiac ventricular myocytes isolated from 12-week-old male MK2+/+ and MK2−/− mice as described previously.43 Briefly, myocytes were incubated with 10 μmol/L Fluo-4 AM (Molecular Probes, Carlsbad, CA), then transferred to a perfusion chamber on the stage of a Zeiss LSM 510 microscope (Carl Zeiss AG, Jena, Germany), and perfused with a Tyrode solution. The perfusion chamber was fitted with bipolar platinum electrodes attached to a Grass SD9 stimulator and maintained at 37°C. To assess Ca²⁺ transients, myocytes were continuously field stimulated at a rate of 2 Hz. To assess the sarcoplasmic reticulum Ca²⁺ content, myocytes first received 10 conditioning pulses at 2 Hz to ensure that each cell had a similar activation history. Upon completion of the conditioning pulses, 10 μmol/L caffeine was applied to the myocyte for 10 seconds via a rapid solution switcher. Changes in free Ca²⁺ were measured in line scan mode with excitation at 488 nm and emission measured at 505 to 530 nm. Myocytes were scanned repeatedly along the length of the cell at 1.5-ms intervals for 7 seconds. Sequential scans were stacked to create a two-dimensional image. Image J (National Institutes of Health, Bethesda, MD) was used to visualize the Ca²⁺ transients, and the data were analyzed with pCLAMP 8.2 (Molecular Devices).

**Isolation of Cardiac Mitochondria and Mitochondrial Respiration Measurements**

Subsarcolemmal mitochondria were isolated from adult mouse hearts as described previously.44 Subsarcolemmal mitochondria were resuspended in KME buffer (100 mmol/L KCl, 50 mmol/L MOPS, 0.5 mmol/L EGTA) at a final concentration of 25 mg mitochondrial protein/mL. To assess respiration, subsarcolemmal mitochondria were suspended (0.25 mg...
protein in 0.5 mL) in a respiration buffer containing 100 mmol/L KCl, 50 mmol/L MOPS, 5 mmol/L KH₂PO₄, 1 mmol/L EGTA, and 0.1% fatty acid-free BSA, pH 7.0. Oxygen consumption was measured using a Clark-type electrode. After recording the basal respiration rate, the following substrate conditions were assessed: (1) 10 mmol/L glutamate plus 5 mmol/L malate, (2) 10 mmol/L pyruvate plus 5 mmol/L malate, (3) 10 mmol/L palmitoyl carnitine plus 5 mmol/L malate, and (4) 10 mmol/L succinate plus 7.5 µmol/L rotenone as previously described. State 3 respiration was measured in the presence of 200 µmol/L ADP, and state 4 respiration was measured with the addition of oligomycin (4 µmol/L).

### Assessing Ca²⁺-Induced Mitochondrial Permeability Transition Pore Opening

The calcium dependency for mitochondrial permeability transition pore (mPTP) opening in subsarcolemmal mitochondria was determined as previously described. In short, mitochondria (0.5 mg) were resuspended in 2.0 mL of assay medium containing 100 mmol/L KCl, 50 mmol/L MOPS, 5 mmol/L KH₂PO₄, 1 mmol/L EGTA, 1 mmol/L MgCl₂, 5 mmol/L glutamate, and 5 mmol/L malate and assayed for Ca²⁺ uptake in a fluorescence spectrophotometer at 37°C. CaCl₂ (5 mmol/L) was infused at a rate of 2 µL/min and the concentration of extramitochondrial free Ca²⁺ was determined using 0.1 mmol/L Fura-6F by monitoring fluorescence emission at 550 nm with excitation wavelengths for the free and calcium-bound forms of 340 and 380 nm, respectively. The cumulative Ca²⁺ load that was required to induce mPTP opening was determined from a semilog plot of the extramitochondrial [Ca²⁺] versus the cumulative Ca²⁺ load and defined as the amount of infused Ca²⁺ required to induce a sharp increase in extramitochondrial [Ca²⁺]. Analyses were done by a single investigator who was blinded as to the identity of the samples.

### Measuring Reactive Oxygen Species

To determine whether abolishing MK2 activity affected mitochondrial generation of reactive oxygen species, hydrogen peroxide production was measured in respiring mitochondria as previously described. Briefly, 0.75 mg of mitochondria were incubated in respiration buffer containing malate and glutamate to which 5 U/mL horseradish peroxidase, 40 U/mL Cu-Zn superoxide dismutase, and 1 µmol/L Amplex Red were added. Superoxide generation was measured with sequential additions of ADP (0.5 mmol/L), oligomycin (1.25 µg/mL), and rotenone (1 µmol/L). H₂O₂ production was measured as an increase in fluorescence of Amplex Red. The experiment was terminated by the addition of 1 nmol H₂O₂ to calibrate the dye response.

### Cardiac Tissue Analyses

#### Histologic Analysis

Hearts were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek USA, Inc., Torrance, CA), and transverse cryosections (8 µm) of the ventricles were prepared and stained with Masson’s trichrome. Two regions on each of 3 separate sections per heart were analyzed by a histology technician who was blinded to the identity of the mice. Images were taken at ×40 using an Olympus BX46 microscope (Olympus Corp., Shinjuku, Japan). Collagen content was quantified by color segmentation using Image Pro Plus version 7 (Media Cybernetics, Rockville, MD) and expressed as a percentage of the surface area. Perivascular collagen was excluded from the measurements. Myocyte diameter was determined in trichrome-stained cryosections using Image Pro Plus.

### Table 1. Primers Used for Quantitative Polymerase Chain Reaction

| Gene       | Name                                    | Genebank ID | Sense | Antisense |
|------------|-----------------------------------------|-------------|-------|-----------|
| Acadm      | Acyl-coenzyme A dehydrogenase, medium-chain | NM_0079382  | GTCGGGTGTCACACAGAG   | TTCTACCCGCGCATCTTCTCCT |
| Gapdh      | Glyceraldehyde-3-phosphate dehydrogenase | NM_008084   | CTGCACCAACAACTGGTTAGC | ACTGTGTCATGAACCCCTTCA |
| Lipe       | Hormone-sensitive lipase                | NM_010719   | GGCACAGACCTCTAAATCCC | CCGCTCTCAGTGAACCCAC |
| Myh7       | β-myosin heavy chain                    | NM_001361607| ACGGGTGGCAAGAGTACGCT | CATCACCTGTCCTCCTTC |
| Nppa       | Atrial natriuretic peptide             | NM_008725   | GTGCATTGTCACACAGAGA | TTCTACCAGCATCTTCTCCTC |
| Pdk4       | Pyruvate dehydrogenase kinase, isoenzyme-4 | NM_013743  | GTGAAGTGTCAGACAGTGC | ATGGTGGGAAAGTGGTGAAGG |
| Pparc1a    | Peroxisome proliferator-activated receptor γ coactivator 1-α | NM_008904  | TGGATGAAGACGAGAAGTC | TGTTTCTGAGTGCTTAAAGAC |
| Ucp3       | Uncoupling protein 3                    | NM_009464   | TCCGATTCAAGCCCATACG | GTCCAGATCCTAGGACACATG |

---

**Ruiz et al** Role of MK2 in Cardiac Function

---

**J Am Heart Assoc.** 2021;10:e017791. DOI: 10.1161/JAHA.120.017791
Total cellular RNA was isolated from transverse cryosections (14 μm) of murine ventricular myocardium using RNeasy Micro kits (Qiagen Inc., Hilden, Germany) with minor modifications. Total RNA was extracted by vortexing tissue section in 300 μL TRIzol reagent (Sigma-Aldrich, St. Louis, MO) for 30 seconds. After incubating at ambient temperature for 5 minutes, 60 μL of chloroform was added, samples were again vortexed and maintained at ambient temperature for an additional 2 to 3 minutes. After centrifugation for 15 minutes at 18 300g and 4°C, the upper aqueous phase was collected, diluted with an equal volume of 70% ethanol, and total RNA purified on Qiagen columns according to the manufacturer’s instructions. Finally, total RNA was eluted with 14 μL of distilled, RNAse-free water. cDNA synthesis was performed as described previously.12

**Figure 1.** MK2 deficiency does not alter survival but enhances aging-dependent weight loss.

A. Scheme showing the long (MK2L) and short (MK2S) forms of MK2 resulting from the use of alternative translation initiation start sites along with the neomycin-resistance gene inserted into the exon encoding catalytic subdomains (SD) V and VI, resulting in an in-frame translation stop codon (NEO-Stop).34,51 B. Representative image showing immunoreactive bands of long (MK2L) and short (MK2S) forms of MK2 in heart lysates from 12-week-old MK2+/+, MK2+/-, and MK2−/− mice. Numbers on left indicate molecular mass (in kDa). C. Kaplan-Meier survival curves for MK2+/+ (n=10) and MK2−/− (n=13) mice up to age 102 weeks. Mantel-Cox tests indicated that the survival curves did not differ significantly (P=0.580). D. Changes in body weight in MK2+/+ and MK2−/− mice up to 102 weeks of age. E. Body weight (BW) and (F) heart weight (HW), both normalized to tibia length (TL) in 102-week-old MK2+/+ and MK2−/− mice. Data are expressed as mean±SEM. *P<0.05, **P<0.01, ***P<0.001. HEK indicates human embryonic kidney; M1, methionine-1; M48, methionine-48; MK2, mitogen-activated protein kinase–activated protein kinase-2; MWt, molecular weight; NES, nuclear export signal; NLS, nuclear localization sequence; and ns, not significant.
Table 2. Echocardiographic Parameters of LV Structure and Function in 12-Week-Old MK2+/+ and MK2−/− Mice

| Parameter                        | MK2+/+     | MK2−/−     |
|----------------------------------|------------|------------|
| **LV structure**                 |            |            |
| LV isovolumetric relaxation time| 0.75±0.007 | 0.76±0.007 |
| LVFW_0 mm                        | 0.736±0.008| 0.740±0.007|
| LVDVP_m mm                       | 4.06±0.03  | 3.90±0.03  |
| LVDVP_m mm                       | 2.61±0.03  | 2.56±0.04  |
| LV mass, mg                      | 111±2      | 102±2      |
| LV mass/LVDVP mg/mm              | 27.2±0.3   | 26.1±0.3   |
| LV mass/BW, mg/g                 | 3.71±0.05  | 3.62±0.05  |
| **LV systolic function**         |            |            |
| LVFS, %                          | 35.9±0.6   | 34.6±0.7   |
| LVEF, %                          | 71.5±0.7   | 69.6±0.9   |
| LVVP_m µL                        | 181±4 (78) | 154±4 (77) |
| LVVP_m µL                        | 51.7±2.2 (79)| 45.4±2.5 (77)|
| SV, µL                           | 34.8±0.8 (76)| 32.2±0.8 (76)|
| CO, mL/min                       | 11.4±0.2 (76)| 9.78±0.2 (76)|
| S_0, cm/s                        | 2.23±0.04  | 2.14±0.04  |
| S_0, cm/s                        | 2.38±0.04  | 2.14±0.04  |
| **LV diastolic function**        |            |            |
| LADs, mm                         | 1.72±0.03 (85)| 1.65±0.04 (90)|
| LAFS, %                          | 20.6±0.5 (85)| 20.4±0.7 (90)|
| Global MPI, %                    | 46.7±1.5 (121)| 52.0±1.5 (126)|
| Septal MPI, %                    | 61.1±2.6 (121)| 61.2±1.8 (121)|
| Lateral MPI, %                   | 62.5±2.6 (121)| 62.9±2.2 (121)|

Table 2. Continued

| Parameter                        | MK2+/+     | MK2−/−     |
|----------------------------------|------------|------------|
| LA dimensions                    |            |            |
| LAD_m mm                         | 2.24±0.03 (107)| 2.12±0.04 (109)|
| LAD_m mm                         | 1.72±0.03 (85)| 1.65±0.04 (90)|
| LAFS, %                          | 20.6±0.5 (85)| 20.4±0.7 (90)|
| Global MPI, %                    | 46.7±1.5 (121)| 52.0±1.5 (126)|

Data are reported as mean±SEM. n=122 and 127 for MK2+/+ and MK2−/−, respectively, unless otherwise indicated by numbers in parentheses. A indicates transmural flow late (atrial) filling velocity; Aa, atrial annulus peak velocity during atrial diastolic filling; AO, aortic output; D, peak velocity during pulmonary venous diastolic flow; E, transmural flow early filling velocity; ED, E wave deceleration; EDT, E wave decay time; E wave, mitral annulus peak velocity during early diastolic filling; IVRT, isovolumetric relaxation time; IVTc, heart rate-corrected IVRT; LAD, left atrial dimension at end cardiac diastole; LADs, left atrial dimension at end cardiac systole; LV, left ventricular; LVFW, left ventricular wall thickness at end cardiac diastole; LVDVP, left ventricular dimension at end cardiac diastole; LVDs, left ventricular dimension at end cardiac systole; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; LVFW, left ventricular posterior wall thickness at end cardiac diastole; LVVP, left ventricular volume at end cardiac diastole; LVP, left ventricular volume at end cardiac systole; MK2, mitogen-activated protein kinase–activated protein kinase-2; MPI, myocardial performance index; S, peak velocity during pulmonary venous diastolic flow; SD slope, pulmonary venous systolic flow decelerating slope; Sb, basal lateral systolic velocity; Sb, basal septal systolic velocity; and SV, stroke volume.

Quantitative polymerase chain reaction was performed by a single observer in a blinded manner. The following genes were selected: (1) key metabolic enzymes, namely, medium-chain acyl-CoA dehydrogenase (Acadm) and hormone-sensitive lipase (Lipe); (2) a transcriptional coactivator acting as a master regulator of mitochondrial function and regulating metabolic gene expression, namely, peroxisome proliferator-activated receptor γ coactivator 1-α (Ppargc1a); (3) mitochondrial uncoupling protein 3 (Ucp3), (4) a marker gene of the fetal phenotype, namely, myosin heavy-chain β (Myh7); and (5) a marker of early cardiac remodeling, namely, atrial natriuretic factor (Nppa). Primers used are listed in Table 1.40,47 The abundance of mitochondrial calcium uptake 2 (Muc2) was performed by TaqMan assay (Assay ID: Mm00801666_g1, FAM-MGB) and normalized to Gapdh (Assay ID: Mm99999915_g1, VIC-MGB) as described previously.48

Biochemical Analyses

Activities of the mitochondrial marker enzymes citrate synthase, succinate dehydrogenase, isocitrate dehydrogenase, and medium-chain acyl–coenzyme A

(Continued)
The myocardial performance index; RV, right ventricular; RVAWd, right ventricular MK2, mitogen-activated protein kinase–activated protein kinase-2; MPI, glutaraldehyde50 before blocking.

lulose, membranes were rinsed in PBS and fixed with Following electrophoretic transfer to 0.22 µm nitrocel -

pulmonary arterial flow acceleration time; A t, transtricuspid flow late (atrial) filling velocity; E m, tricuspid annulus peak velocity during early diastolic filing; systerxial excursion; and TVCO; tricuspid valve closure to opening time.

Table 3. Echocardiographic Parameters of RV Structure and Function in 12-Week-Old MK2+/+ and MK2−/− Mice

|                  | MK2+/+  | MK2−/−  |
|------------------|---------|---------|
| **RV structure** |         |         |
| RVAW  d, mm      | 0.316±0.006 | 0.299±0.007 |
| RVD  d, mm       | 1.81±0.02 | 1.71±0.03* |
| RVAW  d/RVD  d   | 0.175±0.003 | 0.175±0.004 |
| TAPSE, mm        | 1.26±0.02 | 1.2±0.01† |
| **RV systolic function** |         |         |
| S  s, cm/s       | 3.32±0.07 | 2.81±0.07† |
| **RV diastolic function** |         |         |
| Lateral E  s, cm/s | 3.34±0.10 (71) | 2.72±0.08 (65)† |
| Lateral A  s, cm/s | 3.22±0.10 (71) | 2.83±0.11 (65)† |
| Lateral E  s/A  s | 1.09±0.04 (71) | 1.08±0.07 (65) |
| Lateral E  s/E  m | 9.09±0.30 (70) | 10.5±0.4 (65)† |
| **Pulmonary artery flow** |         |         |
| AT, ms           | 21.9±0.75 (78) | 23.1±0.8 (76) |
| AT/RVET          | 26.7±0.7 (75) | 24.9±0.7 (76) |
| **RV MPI**       |         |         |
| TV  cr, ms       | 102±2 (77) | 115±2 (76)† |
| RVET, ms         | 82.2±1.4 (75) | 92±6.1 (76)‡ |
| Lateral MPI, %   | 39±2.8 | 40.4±0.9 |
| Global MPI, %    | 24.5±1.2 (74) | 27.6±1.5 (73) |

Data are reported as means±SEM. n=78 and 77 for MK2+/+ and MK2−/−, respectively, unless otherwise indicated by numbers in parentheses. A  s, tricuspid annulus peak velocity during late (atrial) diastolic filing; AT, pulmonary arterial flow acceleration time; A  s, tricuspid annulus peak velocity early filling deceleration rate; E  DT, tricuspid early filling deceleration rate; MK2, mitogen-activated protein kinase–activated protein kinase-2; MPI, myocardial performance index; RV, right ventricular; RVAW  d, right ventricular anterior wall thickness at end cardiac diastole; RVD  d, right ventricular diameter at end cardiac diastole; RVET, right ventricular ejection time; S  s, right ventricular lateral wall systolic velocity; TAPSE, tricuspid annulus plane systolic excursion; and TV  cr, tricuspid valve closure to opening time.

**Immunoblotting**

SDS-PAGE and immunoblotting were performed as described previously33 with a slight modification. Following electrophoretic transfer to 0.22 µm nitrocel lulose, membranes were rinsed in PBS and fixed with glutaraldehyde50 before blocking.

dehydrogenase were measured spectrophotometri cally in LV myocardium homogenates.45,49

**RESULTS**

There are 2 known variants of MK2, long and short, which result from the use of alternative translation initiation start sites (Figure 1A and 1B).51 The development and general phenotypic characterization of MK2−/− and MK2+/+ mice have been described elsewhere,34 and the abundance of MK2 immuno reactivity in lysates prepared from the ventricular myocardium correlated with genotype (Figure 1B). At 12 weeks of age, MK2-deficient mice had similar body weight (MK2+/+: 29.7±0.4 g, n=141, MK2−/−: 28.7±0.4 g, n=143; P=0.067); at 16 weeks of age, they were characterized by a slight reduction in rectal temperature (MK2+/+: 33.1±0.4°C, n=10, MK2−/−: 32.0±0.4°C, n=12; P<0.05).

**MK2−/− Mice Show Slight Changes Both in LV and RV Function and Bradycardia When Assessed In Vivo**

Echocardiographic Analyses

Echocardiographic imaging at 12 weeks of age revealed a prolonged R-R interval (MK2+/+: 176±3 ms, n=122, MK2−/−: 199±4 ms, n=127; P<0.0001) with modest differences in LV structure and function in MK2-deficient mice (Table 2). In MK2−/− mice, several parameters reflecting LV structure were reduced significantly, including a 3% decrease in LV end-diastolic posterior wall thickness (MK2+/+: 0.736±0.008 mm, n=122, MK2−/−: 0.714±0.007 mm, n=127; P<0.05), a 4% decrease in LV end-diastolic diameter (MK2+/+: 32.0±0.4°C, n=12; P<0.05).
Table 4. MK2 Deficiency Does Not Result in a Progressive Decline in Cardiac Function

|                       |   <6 mo  |   6–12 mo |   12–18 mo |   18–24 mo |
|-----------------------|---------|-----------|------------|------------|
| MK2+/+                |         |           |            |            |
| n                     | 10      | 13        | 10         | 12         |
| R-R interval, ms      | 156±6   | 184±8*    | 148±3      | 178±5*     |
| MK2−/−                |         |           |            |            |
| n                     | 13      | 12        | 12         | 9          |
| R-R interval, ms      | 166±5   | 187±4     | 156±13     | 176±9      |
| LV structure          |         |           |            |            |
| LVAVWd, mm            | 0.716±0.026 | 0.727±0.016 | 0.834±0.017 | 0.850±0.017 |
| LVPauld, mm           | 0.718±0.026 | 0.724±0.018 | 0.803±0.016 | 0.800±0.021 |
| LVDp, mm              | 3.98±0.05     | 3.84±0.12     | 4.20±0.04      | 4.27±0.06    |
| LV mass, mg           | 102±6     | 98.2±6.4     | 132±3        | 139±5       |
| LV mass/LVDp, mg/mm   | 25.6±1.2 | 25.2±1.0    | 31.4±0.7     | 32.3±0.9    |
| LV systolic function  |         |           |            |            |
| LVFS, %               | 38.1±1.2 | 35.3±1.8    | 39.9±0.5     | 36.2±1.2    |
| LVEF, %               | 74.3±1.4 | 69.5±2.3    | 76.4±0.5     | 71.5±1.6    |
| S1, cm/s              | 2.58±0.11 | 2.33±0.10   | 2.86±0.08    | 2.44±0.09   |
| S2, cm/s              | 2.28±0.11 | 2.08±0.08   | 2.74±0.10    | 2.36±0.08*  |
| LV diastolic function |         |           |            |            |
| Transmitr flow        |         |           |            |            |
| E, cm/s               | 60.4±1.9 | 53.2±3.9    | 68.1±1.4     | 62.4±1.5    |
| E′, cm/s              | 34.3±1.2 | 40.4±2.2    | 34.0±1.5     | 40.7±1.4†   |
| E′/E                  | 1.97±1.2 | 14.3±1.3†   | 2.09±0.7     | 16.0±0.8*†  |
| A, cm/s               | 44.3±2.1 | 49.0±2.4    | 47.4±1.9     | 51.9±1.8    |
| E′/A                  | 1.31±0.04 | 1.06±0.07   | 1.40±0.06    | 1.20±0.05†  |
| Lateral Eam, cm/s     | 2.43±0.12 | 1.75±0.12*  | 2.52±0.14    | 1.98±0.15†  |
| Lateral E′am, cm/s    | 0.796±0.065 | 0.723±0.050 | 0.818±0.044 | 0.664±0.061 |
| Septal Eam, cm/s      | 26.3±1.7 | 25.7±1.8    | 28.6±1.9     | 36.1±2.0    |
| Septal E′am, cm/s     | 2.30±0.24 | 1.95±0.15   | 2.53±0.17    | 2.11±0.19   |
| Pulmonary venous flow |         |           |            |            |
| S/D mean              | 1.28±0.10 | 1.22±0.09   | 1.19±0.09    | 1.40±0.06   |
| LV isovolumetric relaxation time | | | | |
| IVRTc                 | 1.34±0.05 | 1.36±0.07   | 1.22±0.06    | 1.43±0.06   |
| LA dimensions         |         |           |            |            |
| LADs, mm              | 2.06±0.10 | 1.67±0.06†  | 2.37±0.06    | 2.40±0.06   |

(Continued)
Table 4. Continued

| Time (mo) | MK2+/+ | MK2−/− | MK2+/+ | MK2−/− | MK2+/+ | MK2−/− | MK2+/+ | MK2−/− |
|-----------|---------|---------|---------|---------|---------|---------|---------|---------|
| <6 mo     |         |         |         |         |         |         |         |         |
| LADd, mm  | 1.68±0.10 | 1.31±0.07§ | 1.92±0.05 | 1.94±0.06 | 2.33±0.16 | 2.45±0.09 | 2.64±0.12 | 2.63±0.12† |
| LAFS, %   | 18.9±1.1 | 22.6±1.4 | 19.3±0.8 | 19.2±1.1 | 19.0±1.5 | 18.9±1.3 | 14.2±1.2 | 17.3±1.7 |
| MPI       |         |         |         |         |         |         |         |         |
| Septal MPI, % | 72.1±5.0 | 67.7±3.4 | 69.5±4.7 | 71.1±2.6 | 44.0±4.1 | 48.3±3.2 | 60.9±4.3 | 59.8±4.3 |
| Lateral MPI, % | 69.9±5.3 | 64.0±2.5 | 69.5±5.1 | 73.6±4.4 | 42.2±4.4 | 57.4±4.4 | 59.3±7.0 | 51.9±4.3 |
| Global MPI, % | 41.0±3.3 | 57.2±2.9‡ | 33.0±3.2 | 49.2±3.9* | 25.2±2.8 | 42.6±2.6§ | 37.9±6.6 | 47.3±4.7 |

Data reported as mean±SEM. A indicates transmitral flow late (atrial) filling velocity; A_0 indicates mitral annulus peak velocity during atrial diastolic flow; CO, cardiac output; D, peak velocity during pulmonary venous diastolic flow; E indicates transmitral flow early (systolic) filling velocity; ED, E wave deceleration; EDT, E wave deceleration time; E_m, mitral annulus peak velocity during early diastolic filling; FS, fractional shortening; IVRT, isovolumic relaxation time; IVRTc, heart rate-corrected IVRT; LAD, left atrium dimension at end cardiac diastole; LAD_s, left atrium dimension at end cardiac systole; LVAW, lateral ventricular anterior wall thickness; LVVs, left ventricular volume at end cardiac systole; MK2, mitogen-activated protein kinase–activated protein kinase-2; MPI, myocardial performance index; S, peak velocity during pulmonary venous systolic flow; SD slope, pulmonary venous systolic flow decelerating slope; SDi, mitral annulus peak velocity during atrial diastolic filling; TAPSE, tricuspid annular plane systolic excursion; TRIC, tricuspid regurgitation Doppler jet; VTI, velocity time integral; VTIi, filter-corrected velocity time integral; VS, mitral/annulus peak systolic tissue velocities; VV_s, left ventricular volume at end cardiac systole; WMSI, wall motion score index.

§P <0.05 for MK2−/− vs MK2+/+.
†P <0.05 for an interaction between the effects of genotype and age.
‡P <0.05 for MK2−/− vs MK2+/+.
§P <0.001 for MK2−/− vs MK2+/+.
||P <0.0001 for MK2−/− vs MK2+/+.

Significantly different in MK2+/+ (71.5±0.7%; n=122) versus MK2−/− (69.6±0.9%; n=127) mice. Consistent with a reduced LV end-diastolic diameter and increased cardiac cycle length, cardiac output was reduced by 14% (MK2+/+: 11.4±0.2 mL/min, n=76; MK2−/−: 9.78±0.28 mL/min, n=76; P<0.0001) and both septal (MK2+/+: 2.38±0.04 cm/s, n=122; MK2−/−: 2.14±0.04 cm/s, n=127; P<0.001) and lateral (MK2+/+: 2.23±0.04 cm/s, n=122; MK2−/−: 1.98±0.04 cm/s, n=127; P<0.0001) wall systolic tissue velocities were decreased. Assessment of diastolic function revealed that the LV isovolumetric relaxation time, corrected for the differences in R-R interval, was prolonged by 16% in MK2−/− mice (rate-corrected isovolumetric relaxation time; MK2+/+: 35.2±0.8 ms, n=122; MK2−/−: 38.7±0.8 ms, n=127; P<0.01) and deceleration rate reduced by 9.6% (MK2+/+: 22.8±0.6 m/s², n=122; MK2−/−: 20.6±0.6 m/s², n=127; P<0.01) in MK2−/− hearts. Both septal and LV lateral mitral annular motion velocities (E_m, A_0) were reduced in MK2-deficient hearts, resulting in an increase in the ratio of transmitral early filling velocity to both lateral (MK2+/+: 36.7±1.0, n=110; MK2−/−: 40.0±1.1, n=121; P<0.05) and septal (MK2+/+: 29.3±0.6, n=112; MK2−/−: 32.7±0.7, n=120; P<0.0001) early diastolic mitral annular velocities, suggesting reduced LV compliance. Impaired LV compliance increases left atrial (LA) afterload and could result in LA enlargement. MK2−/− mice actually showed a slight decrease in LA diameter during systole (MK2+/+: 1.26±0.02 mm, n=122; MK2−/−: 1.21±0.01 mm, n=77; P<0.05) in
MK2−/− mice as was the RV systolic tricuspid annular velocity (MK2+/+: 3.32±0.07 cm/s, n=78; MK2−/−: 2.81±0.07 cm/s, n=77; P<0.0001). In terms of RV diastolic function, peak velocities of early (E) and late (A) RV filling, in addition to the early RV filling wave deceleration time and deceleration rate, were similar in MK2+/+ and MK2−/− hearts. Both early (Eₐ; MK2+/+: 3.34±0.10 cm/s, n=71; MK2−/−: 2.72±0.08 cm/s, n=65; P<0.0001) and late (Aₐ; MK2+/+: 3.22±0.10 cm/s, n=71; MK2−/−: 2.83±0.11 cm/s, n=72, P<0.01) diastolic lateral

**Figure 2.** MK2−/− mice exhibited a slower heart rate in vivo. A, In vivo heart rate assessment by surface electrocardiography in MK2+/+ (n=7) and MK2−/− (n=7) mice anesthetized with isoflurane. Arrow indicates injection of isoproterenol (ISO; 0.1 mg/kg). *P<0.05 MK2+/+ vs MK2−/−, repeated-measures 2-way ANOVA with Bonferroni posttest. B, Representative ECGs obtained by radio telemetry in conscious unrestrained 12-week-old male MK2+/+ (upper) and MK2−/− (lower) mice. C, Mean heart rates obtained from ECGs recorded over a 48-hour time period by radio telemetry in conscious unrestrained MK2+/+ (n=6) and MK2−/− (n=6) mice. Data were extracted and analyzed in 3 hour intervals and then averaged separately for each mouse before calculating the mean heart rate for each group. D, Heart rates obtained from ECGs recorded over a 48-hour time period by radio telemetry in conscious unrestrained MK2+/+ (n=6) and MK2−/− (n=6) mice. Data were extracted and analyzed in 3 hour intervals. Mice were maintained on a 12:12 hour light:dark cycle (18h00:6h00) with the bar at the top of the graph indicating light and dark cycles. The circadian rhythm is clearly visible. E, R-R interval and (F) P-R segment duration obtained from ECGs recorded over a 48-hour time period by radio telemetry in conscious unrestrained MK2+/+ and MK2−/− mice. Data were extracted and analyzed in 3-hour intervals and then values for light and dark cycles averaged separately for each mouse before calculating the mean heart rate for each group. G, Mean 48 hour SD1/SD2 ratios for MK2+/+ (n=6) and MK2−/− (n=6) mice where SD1 represents the standard deviation on the short axis and SD2 represents the standard deviation on the long axis of an ellipse fit to a plot of R-Rₙ vs R-Rₙ₊₁. Data are expressed as mean±SEM. *P<0.05, **P<0.01. MK2 indicates mitogen-activated protein kinase–activated protein kinase-2.
tricuspid annular motion velocities were reduced in MK2-deficient hearts, resulting in a 16% increase in the ratio of trans-tricuspid early filling velocity to early diastolic tricuspid annular velocity (E/E_m; MK2+/+: 9.09±0.30, n=70; MK2−/−: 10.5±0.4, n=65; P<0.01). Hence, echocardiographic assessment revealed that the deletion of MK2 resulted in changes in RV function similar to those observed in the LV.

We then examined the possible effect(s) of an MK2-deficiency on cardiac aging. Mantel-Cox tests indicated that the survival curves for wild-type (10) and MK2-deficient (13) male littermates did not differ significantly when assessed up to 102 weeks of age (Figure 1C, P=0.580). Although both MK2+/+ and MK2−/− mice initially appeared to age similarly, body weight in MK2−/− mice peaked at 60 weeks of age and then began to decrease, whereas that of wild-type mice peaked at around 80 weeks of age (Figure 1D). At 102 weeks of age, the body weight of surviving MK2−/− mice was 29% lower than that of surviving MK2+/+ mice (MK2+/+: 22.6±0.4 g/mm, n=4; MK2−/−: 1.55±0.16 g/mm, n=5; P<0.05) when normalized to tibia length (Figure 1E). At 102 weeks of age, the body weight of surviving MK2−/− mice was 14% lower than that of surviving MK2+/+ mice (MK2+/+: 2.29±0.16 g/mm, n=4; MK2−/−: 1.55±0.16 g/mm, n=5; P<0.05) when normalized to tibia length (Figure 1F), which did not reach significance. Food and water consumption of 88-week-old MK2-deficient mice did not differ significantly from that of wild-type littermates (data not shown). Cardiac structure and function were assessed in MK2+/+ and MK2−/− mice by echocardiography every 4 weeks (weeks 12–28) or 8 weeks (weeks 28–100) weeks until 102 weeks of age. Data for each parameter were then binned into 4 age ranges (<6, 6–12, 12–18, 18–24 months) for each mouse and the mean and SEM determined for MK2+/+ and MK2−/− mice (Table 4). MK2−/− mice displayed a prolonged R-R interval throughout the study; however, in the second year of life, the difference no longer reached significance. Throughout the duration of the study, LV ejection fraction and fractional shortening in MK2-deficient mice did not differ significantly from that of wild-type littermates, indicating that systolic function was unaffected. When examined at 3 months of age, MK2-deficient mice showed signs of reduced compliance, suggesting early diastolic dysfunction (Table 2); however, this condition did not progress with age (Table 4). Specifically, peak E and A wave velocities, as well as regional E/E_m ratios, did not differ significantly. E wave deceleration times were prolonged and the deceleration rate tended to be significantly slower in MK2−/− mice. Furthermore, in MK2-deficient mice, aging was not associated with LA dilation or changes in the pulmonary venous flow systolic/diastolic ratio, which are hallmarks of diastolic dysfunction. However, although the left atria were significantly smaller in MK2−/− mice, this difference was lost with age, suggesting that there may have been some degree of atrial remodeling in these mice over time. In summary, the absence of MK2 was associated with weight loss but no age-related progressive deterioration in systolic or diastolic function.

### Heart Rate and Electrocardiography in Conscious Mice

As mentioned above, echocardiographic imaging, obtained under isoflurane anesthesia, revealed the R-R interval was prolonged in MK2−/− mice (Table 2), indicating a lower heart rate in these mice (MK2+/+: 341±20 beats/min, n=122; and MK2−/−: 306±17 beats/min, n=127; P<0.0001). Analysis by surface ECG revealed that when mice under isoflurane anesthesia were challenged with a single dose of isoproterenol (0.1 mg/kg), the heart rate of MK2−/− mice and MK2+/+ mice increased to similar levels, whereas heart rate declined more rapidly in MK2−/− mice (Figure 2A). However, isoflurane lowers heart rate53 and could, possibly, affect MK2+/+ and MK2−/− mice differently. Hence, we next evaluated cardiac electrical activity in conscious unrestrained mice by radio telemetry over a period of 48 hours. Overall, the mean R-R interval in MK2−/− mice was 7% longer in comparison to their littermate MK2+/+ mice even in the absence of anesthetic (MK2+/+: 115±3 ms, n=6; MK2−/−: 123±2 ms, n=6; P<0.05) (Table 5). Stated otherwise, the heart rate in MK2+/+ mice was 53±8 bpm (n=4), whereas that of MK2−/− mice was 96±8 bpm (n=6; P<0.05) (Table 5, Figure 2C). In addition, the duration of the P-R segment was longer in MK2+/+ mice (MK2+/+: 22.6±0.4 ms, n=5; MK2−/−: 25.9±1.0 ms, n=4; P<0.05) whereas the P wave duration, QRS duration, and QTc were unaffected (Table 5). An
examination of the circadian rhythm pattern of heart rate revealed MK2-deficient mice showed prolonged R-R intervals (Figure 2D and 2E) and P-R segments (Figure 2F) during both light and dark cycles. We next performed a nonlinear analysis of heart rate variability by plotting the R-R interval in the form of Poincaré plots (R−Rn versus R−Rn+1), fitting the data to an ellipse, and determining the SD on the short (SD1) and long (SD2) axes of the ellipse. SD1 reflects short-term variability in heart rate, whereas SD2 reflects both short-term and long-term variability. The SD1/SD2 ratio was significantly greater in MK2-deficient mice (Figure 2G). Both prolonged P-R segment, reflecting atrioventricular nodal conduction times, and increased short-term variability in heart rate suggest autonomic regulation of heart rate is altered in MK2-deficient mice.

**Calcium Transients Are Similar in Isolated Ventricular Cardiomyocytes From MK2+/+ and MK2−/− Mice**

In light of the differences in R-R interval and diastolic function observed in MK2−/− mice (Table 2, Table 4, Figure 2), we examined the effect of an MK2-deficiency on the amplitude and decay of Ca²⁺ transients evoked by field stimulation (2 Hz; Figure 3A through 3C) or superfusion with caffeine (10 seconds,
10 μmol/L; Figure 3D through 3G) in isolated adult cardiac ventricular myocytes. Representative transients from MK2+/+ and MK2−/− myocytes are respectively shown in Figure 3A and 3D. The mean data show in both conditions that neither the amplitude of the cytosolic Ca2+ transient nor the time to 90% transient decay for Ca2+-transients differed significantly in cardiomyocytes from MK2+/+ and MK2−/− mice after field stimulation (Figure 3B and 3C) or following caffeine superfusion (Figure 3E and 3F). In addition, the fractional release of Ca2+, calculated by dividing the amplitude of the depolarization-induced Ca2+ transient by that of the caffeine-induced transient, was also similar in MK2+/+ and MK2−/− myocytes (Figure 3G).

Hence, the absence of MK2 did not significantly alter the Ca2+ content of cardiomyocyte sarcoplasmic reticulum or its capacity for Ca2+ release and reuptake.

### Heart Rate Normalizes When Hearts From MK2−/− Mice Are Perfused Ex Vivo in Working Mode

To determine if the observed bradycardia involved mechanisms intrinsic to the MK2-deficient heart, we next examined heart function in isolated hearts. The heart simultaneously uses multiple substrates for energy production (carbohydrate±fatty acid) and genotype; P<0.05.

| Parameter | Control | +Isoproterenol | +Palmitate |
|-----------|---------|---------------|----------|
| n         | MK2+/+  | MK2−/−        | MK2+/+  | MK2−/−        | MK2+/+  | MK2−/−        |
| Heart rate, beats/min | 463±27 | 491±19 | 590±18* | 575±12† | 352±14* | 323±14† |
| Stroke volume, μL | 26.8±3.6 | 24.2±2.0 | 22.3±2.4 | 20.4±1.6 | 31.5±1.3 | 31.3±1.8 |
| Systolic ejection period, ms | 28.8±3.6 | 31.1±2.4 | 24.1±2.5 | 25.9±1.0 | 40.1±2.1† | 41.5±2.6 |
| Diastolic filling period, ms | 64.7±8.8 | 44.5±3.3 | 33.0±3.1† | 40.6±1.0* | 83.6±7.0 | 97.3±12.1† |
| LVSP, mm Hg | 113±5 | 122±5 | 122±5 | 137±6 | 103±3 | 103±2† |
| LVEDP, mm Hg | 5.63±4.37 | 8.00±2.5 | 3.00±2.80 | 1.80±6.14 | 7.09±0.89 | 9.00±0.92 |
| P<0, mm Hg | −7.75±1.99 | −18.7±1.99† | −13.3±2.2 | −27.1±3.5* | −5.73±1.68 | −5.45±1.45†† |
| Developed pressure, mm Hg | 121±6 | 141±7 | 135±8 | 164±8†† | 110±5 | 108±2††† |
| +dP/dt, mm Hg/s | 6096±612 | 5822±488 | 7112±730 | 6780±551 | 5245±176 | 5029±173 |
| −dP/dt, mm Hg/s | 4609±198 | 5357±215 | 5978±451 | 7347±523** | 3860±159 | 3424±152** |
| Contraction time, ms | 24.3±2.7 | 27.5±3.3 | 27.4±3.8 | 32.3±2.4 | 30.0±3.7 |
| Relaxation time, ms | 22.4±3.0 | 19.9±1.9 | 17.4±1.7 | 19.7±1.4 | 17.3±2.4 | 19.7±2.8 |
| Contractility index, 1/s | 103±8 | 89.9±5.5 | 103±10 | 89.8±8.1 | 94.8±5.6 | 95.9±4.2 |
| Tau W, ms | 8.6±1.4 | 6.5±0.8 | 6.7±0.6 | 5.7±0.8 | 6.5±1.2 | 8.0±1.5 |
| Coronary flow, mL/min | 3.63±0.59 | 4.05±0.42 | 4.35±0.39 | 4.91±0.36 | 2.96±0.54 | 2.46±0.25 |
| Aortic flow, mL/min | 8.34±1.35 | 7.60±0.53 | 8.84±1.64 | 8.60±0.88 | 8.02±0.60 | 7.58±0.32 |
| Rate pressure product, mm Hg·beats/min×10−3 | 55.6±4.1 | 68.9±3.0 | 80.3±5.2† | 94.1±4.9† | 38.4±2.0* | 35.5±2.2††† |
| Cardiac output, mL/min | 12.0±1.3 | 11.6±0.6 | 13.2±1.5 | 11.7±0.9 | 11.0±0.4 | 10.0±0.3 |
| Cardiac power, mW | 3.30±0.46 | 3.69±0.29 | 4.05±0.53 | 4.27±0.42 | 2.68±0.16 | 2.40±0.10 |
| MVO2, μmol/min | 1.45±0.19 | 1.77±0.18 | 2.24±0.31 | 2.26±0.17 | 1.19±0.23 | 0.87±0.10† |
| Cardiac efficiency, mW·min/μmol | 2.66±0.40 | 2.23±0.31 | 2.23±0.26 | 2.10±0.39 | 3.29±0.85 | 2.88±0.24 |
| LDH release | 13.7±3.0 | 13.4±3.9 | 15.5±3.7 | 16.2±3.5 | 12.4±2.8 | 12.8±1.7 |

Data reported as mean±SEM. HR indicates heart rate; LDH, lactate dehydrogenase; LVEDP, left ventricular end diastolic pressure; LVSP, left ventricular systolic pressure; MK2, mitogen-activated protein kinase–activated protein kinase-2; MVO2, oxygen consumption; and P<0, minimum diastolic pressure.

*P<0.001 vs control-MK2+/+.
†P<0.005 vs control-MK2−/−.
‡P<0.001 vs control-MK2−/−.
§P<0.05 vs control-MK2+/+.
||P<0.05 vs control-MK2+/+.
¶Indicates a significant interaction between the effects of isoproterenol and genotype; P<0.05.
#P<0.0001 vs iso-MK2+/+.
**P<0.001 vs control-MK2−/−.
††Indicates a significant interaction between the effects of substrate for energy production (carbohydrate±fatty acid) and genotype; P<0.05.
‡‡P<0.001 vs control-MK2+/+.
§§P<0.01 vs control-MK2−/−.
production; hence, cardiac function was examined in the presence of (1) exogenous carbohydrates and (2) exogenous carbohydrates plus palmitate as energy sources. First, in contrast to observations of heart rate made in vivo, when hearts were perfused ex vivo in a semirecirculating working mode, heart rates in MK2+/+ and MK2−/− mice were similar (MK2+/+: 463±27 beats/min, n=8; MK2−/−: 491±19 beats/min, n=10; Table 6, Figure 4). Our assessment of heart function ex vivo included evaluating the response to isoproterenol wherein hearts from MK2+/+ and MK2−/− mice were perfused in working mode for 20 minutes, after which isoproterenol (10 nmol/L) was added to the perfusion buffer for an additional 20 minutes. Hearts from both MK2−/− and MK2+/+ mice responded to the presence of isoproterenol in the perfusate with an increase in heart rate, and this increase was of similar magnitude (Table 6, Figure 4). When perfused with buffer containing isoproterenol, values for most LV function parameters, especially related to systolic function and cardiac flow, remained unchanged in both MK2+/+ and MK2−/− hearts, although LV developed pressure increased significantly in MK2-deficient but not wild-type hearts. Similarly, isoproterenol induced a significant increase in the maximum rate of relaxation in MK2-deficient but not wild-type hearts compared with baseline. The mouse heart normally derives more than half of its energy requirements from fatty acid oxidation. No functional differences were observed between MK2+/+ and MK2−/− hearts when perfused in the presence of palmitate (0.6 mmol/L), although it is worth noting that with the addition of palmitate to the perfusing buffer, there were more functional changes in MK2-deficient hearts, relative to carbohydrates alone as the exogenous energy source, than observed in wild-type hearts (Table 6). Overall, it was interesting to note that, whereas MK2-deficient hearts were bradycardic when assessed in vivo, when cardiac function was assessed ex vivo in an isolated working heart preparation, no difference in heart rate was observed.

MK2−/−-Mice Are Characterized by Changes in Transcript Abundance for Metabolic Genes and Decreased Sensitivity for mPTP Opening

Although it is estimated that mitochondria contribute marginally to Ca2+ removal during global Ca2+ transients in healthy cardiomyocytes, mitochondria

---

**Table 7. Mitochondrial Parameters From MK2−/− and MK2+/+ Hearts**

|                  | MK2+/+ | MK2−/− |
|------------------|--------|--------|
| n                | 8      | 8      |
| Mitochondrial respiration, ng oxygen atoms/mg per min Glutamate+malate | 130±6 | 141±12 |
| State 3          | 33.0±2.0 | 38.6±2.4 |
| RCR              | 4.3±0.4 | 3.6±0.2 |
| Pyruvate+malate  |        |        |
| State 3          | 412±17 | 455±24 |
| State 4          | 55.2±4.7 | 62.0±3.2 |
| RCR              | 8.2±0.6 | 7.4±0.5 |
| Palmitoyl-carnitine+malate | 441±21 | 399±38 |
| State 4          | 49.7±5.9 | 45.0±4.6 |
| RCR              | 8.8±1.3 | 10.1±1.0 |
| Succinate+rotenone | 467±29 | 423±26 |
| State 3          | 167±18 | 166±15 |
| State 4          | 3.7±0.7 | 2.7±0.2 |
| Mitochondrial enzymatic activities |        |        |
| CS activity, μmol/mg/min | 1.76±0.12 | 1.66±0.06 |
| MCAD activity, μmol/mg per min | 0.18±0.01 | 0.18±0.01 |
| SD activity, μmol/mg per min | 0.015±0.001 | 0.020±0.001* |
| ICDH activity, mmol/mg per min | 1.29±0.15 | 1.08±0.07 |
| Mitochondrial H2O2 production rate, nmol/min per mg |        |        |
| State 3          | 0.07±0.01 | 0.07±0.01 |
| State 4          | 0.37±0.03 | 0.38±0.02 |

Data are mean±SEM. CS indicates citrate synthase; ICDH, isocitrate dehydrogenase; MCAD, medium chain acyl-CoA dehydrogenase; MK2, mitogen-activated protein kinase–activated protein kinase-2; SD, succinate dehydrogenase. *P<0.05, MK2+/+ vs MK2−/−.
occupy ≈30% of the volume of a cardiomyocyte and may therefore influence diastolic Ca\(^{2+}\). In this regard, and because of the age-dependent weight loss observed in MK2-deficient mice, we examined certain aspects of mitochondria function. First, we evaluated function in isolated mitochondria by measuring oxygen consumption in state 3 and state 4. Compared with mitochondria from wild-type hearts, those from MK2\(^{-/-}\) hearts showed no difference in mitochondrial respiration, irrespective of substrates used, or in mitochondrial generation of reactive oxygen species, specifically hydrogen peroxide (Table 7). However, mitochondria from MK2\(^{-/-}\) hearts showed a decreased sensitivity for mPTP opening as evidenced with mitochondria from wild-type hearts, those from MK2\(^{-/-}\) hearts showed no difference in mitochondrial respiration, irrespective of substrates used, or in mitochondrial generation of reactive oxygen species, specifically hydrogen peroxide (Table 7). However, mitochondria from MK2\(^{-/-}\) hearts showed a decreased sensitivity for mPTP opening as evidenced

Figure 5. Calcium-sensitivity in isolated mitochondria from 12-week-old MK2\(^{-/-}\) mice showed delayed mitochondrial permeability transition pore (mPTP) opening compared with their littermate counterparts. Subsarcolemmal mitochondria were isolated from MK2\(^{-/-}\) and MK2\(^{+/+}\) hearts and assessed for their ability to buffer extramitochondrial calcium. A, Low calcium loads are sustainable by mitochondria; however, when a threshold calcium load is attained, a large and abrupt increase in extramitochondrial calcium signifies opening of the mPTP. B, The abundance of the mitochondrial Ca\(^{2+}\) uptake 2 (Micu2) mRNA, a regulatory subunit of the mitochondrial inner membrane Ca\(^{2+}\) uniporter, in the ventricular myocardium. C, The abundance of immunoreactivity of the different proteins responsible for mitochondrial permeability transition. Cytochrome c oxidase subunits 1 (COX-I) and 4 (COX-IV) immunoreactivity served as loading controls. Data are expressed as mean±SEM (n=8). *P<0.05, **P<0.001, ***P<0.0001, MK2\(^{+/+}\) vs MK2\(^{-/-}\). ANT indicates adenine nucleotide translocase; AU, arbitrary units; CYP-D, cyclophilin-D; MK2, mitogen-activated protein kinase–activated protein kinase-2; and VDAC, voltage-dependent anion channel.
Ruiz et al Role of MK2 in Cardiac Function

by the greater cumulative calcium load needed to trigger mPTP opening (Figure 5A). Interestingly, this occurred despite no significant changes in the abundance of immunoreactivity of different proteins putatively involved in the cardiac mPTP complex, namely, cyclophilin-D, voltage-dependent anion channel, and adenine nucleotide translocase (Figure 5C).

Cytochrome c oxidase subunits I and 4 served as loading controls for mitochondrial protein (Figure 5C). As single-nucleotide polymorphisms in the mitochondrial calcium uptake 2 (MICU2/EFHA1) gene have been associated with changes in P-R segment duration,54 transcript levels for Micu2 were assessed by quantitative polymerase chain reaction and found to be reduced in hearts from MK2−/− mice (Figure 5B).

At the metabolic level, although serum glucose, free fatty acids, triglycerides, and ketone body levels did not differ between MK2−/− mice and MK2+/+ mice (data not shown), the abundance of mRNAs encoding medium-chain acyl–coenzyme A dehydrogenase, hormone-sensitive lipase, peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α), and uncoupling protein 3 were significantly higher in ventricular myocardium from MK2−/− mice compared with controls (Figure 6). In addition, the activity of mitochondrial enzymes isocitrate dehydrogenase, citrate synthase, and medium-chain acyl–coenzyme A dehydrogenase was similar between both groups, whereas that of succinate dehydrogenase activity was increased by 30% in mitochondria from MK2−/− hearts (MK2+/+: 0.015±0.001 μmol/mg per minute, n=8; and MK2−/−: 0.020±0.001 μmol/mg per minute, n=8; P<0.05; Table 7).

Pressure Overload–Induced Myocardial Remodeling Is Not Prevented in MK2-Deficient Mice

Given (1) the above-mentioned marginal effects of MK2 deletion on baseline cardiac function; (2) the cardioprotective effects of an MK2-deficiency in a streptozotocin model of diabetes mellitus;33 (3) increased afterload induced by TAC both activates p38 MAPKs and increases phosphorylation of hsp25 at residues phosphorylated by MKs 2, 3, and 5 (serine-15, serine-82)12,55; and (4) the hypertrophic cardiomyopathy resulting from an acute, cardiomyocyte-specific activation of the p38 pathway in adult mice is attenuated by MK2 deficiency,21 we next assessed the effect of MK2-deficiency on cardiac remodeling in response to TAC. Twelve-week-old male MK2-deficient and wild-type littermate male mice underwent TAC and were sacrificed 2 or 8 weeks after surgery, as described previously.40 Invasive hemodynamic assessment revealed that TAC induced increases in both peak systolic arterial pressure and peak LV pressure that did not differ significantly between TAC-MK2+/+ and TAC-MK2−/− groups (Table 8, Figure 7A) with an average overall increase in peak systolic arterial pressure of 40 mm Hg. In addition, echocardiographic imaging of the aortic arch revealed comparable flow velocities at the site of constriction in TAC-MK2+/+ and TAC-MK2−/− groups (Table 9). Hence, an increase in afterload was similarly established in both

![Figure 6. MK2−/− mice showed changes in specific mitochondrial-associated markers.](image-url)

The abundance of mRNA for genes encoding (A) medium-chain acyl-CoA dehydrogenase (Acadm), (B) hormone-sensitive lipase (Lipe), (C) peroxisome proliferator-activated receptor γ coactivator 1α (Ppargc1a), (D) uncoupling protein 3 (Ucp3), and (E) pyruvate dehydrogenase kinase 4 (Pdk4) was evaluated on RNA isolated from the ventricular myocardium. Data were normalized to the abundance of Gapdh mRNA. Values shown were normalized to that of a representative MK2+/+ mouse and expressed as means±SEM. n=4 mice/group. *P<0.05, **P<0.01, MK2+/+ vs MK2−/−. *P<0.05, **P<0.01, MK2+/+ vs MK2−/−. MK2 indicates mitogen-activated protein kinase–activated protein kinase-2.
MK2+/+ and MK2−/− mice. Two weeks after TAC, echocardiographic imaging revealed LV mass increased by 47% (sham: 103±3 mg, n=17; TAC: 151±8 mg, n=16; P<0.0001) in MK2+/+ mice, which was attenuated to an increase of 9% in MK2-deficient mice that did not reach statistical significance (sham: 112±6 mg, n=14; TAC: 128±7 mg, n=15; P>0.05). Similarly, heart weight to tibia length ratios were increased by 37% in MK2+/+ mice (sham: 67.9±3.9 mg/cm, n=8; TAC: 92.8±5.1 mg/cm, n=10; P<0.05; Figure 7B). Pathological LV hypertrophy is associated with molecular remodeling that includes the reexpression of the cardiac fetal genes atrial natriuretic peptides (Nppa) and β-myosin heavy chain (Myiβ). Nppa and Myiβ mRNA levels were quantified by quantitative polymerase chain reaction 2 weeks after TAC. Although hypertrophy was significant in MK2+/+ but not MK2−/− mice 2 weeks after TAC, Nppa [Figure 8A] and Myiβ (Figure 8B) mRNA levels in MK2+/+ and MK2−/− hearts increased to similar levels. Eight weeks after TAC, LV mass was similarly increased in MK2+/+ mice by 64% (sham: 106±3 mg, n=11; TAC: 174±14 mg, n=11; P<0.0001) and in MK2−/− mice by 50% (sham: 109±3 mg, n=11; TAC: 164±8 mg, n=10; P<0.0001) (Table 9). Similarly, 8 weeks after TAC, LV myocyte diameter in MK2+/+ and MK2−/− hearts did not differ significantly (data not shown). Hence, although LV hypertrophy was not significant in MK2-deficient mice 2 weeks after TAC, the absence of MK2 did not prevent hypertrophy in response to a chronic increase in afterload.

Direct hemodynamic assessment by Millar catheter did not reveal major functional differences between TAC-MK2+/+ and TAC-MK2−/− mice; however, at both 2 and 8 weeks after TAC, MK2-deficient hearts showed a significant increase in the maximum rate of relaxation relative to sham MK2−/− mice, whereas MK2+/+ mice did not (Table 8). Assessment of LV structure and function by echocardiographic imaging 2-weeks after TAC revealed reduced end-diastolic diameter in TAC MK2−/− mice compared with both their sham counterparts (sham: 4.14±0.07 mm, n=14; TAC: 3.84±0.07 mm, n=15; P<0.05) and TAC MK2+/+ mice (4.18±0.08 mm, n=16; P<0.05 versus TAC MK2−/−). Eight weeks after TAC, these differences were no longer significant. LV anterior and posterior wall thicknesses were increased to a similar extent in both TAC MK2+/+ and TAC MK2−/− mice (≈20%; P<0.001; Table 9). LV ejection fraction was reduced in MK2+/+ mice 2 weeks after TAC (sham: 68.8±1.8%, n=17; TAC: 59.9±3.0%, n=16; P<0.05), whereas it was increased in MK2−/− mice (sham: 64.4±2.0%, n=14; TAC: 73.6±1.4%, n=15; P<0.05) with left ventricular ejection fraction being 23% greater in TAC MK2−/− mice than TAC MK2+/+ mice (P<0.001). Although these

### Table 8. Hemodynamic Parameters for MK2+/+ and MK2−/− Mice 2 and 8 Weeks After TAC

| Parameter | Sham Operation | TAC | Sham Operation | TAC |
|-----------|----------------|-----|----------------|-----|
| n | 8 | 8 | 11 | 10 |
| BPmax, mm Hg | 99.4±5.3 | 89.4±2.9 | 129±9 | 139±10† |
| LVPmax, mm Hg | 103±8 | 90.5±2.2 | 139±11 | 143±12† |
| LVPmin, mm Hg | 3.3±0.9 | 4.3±0.9 | 4.8±1.8 | 3.5±1.3 |
| +dP/dt, mm Hg/s | 5713±257 | 4571±254 | 6355±441 | 5788±525 |
| −dP/dt, mm Hg/s | 5336±294 | 4038±221 | 6500±629 | 6823±753‡ |
| LVEDP, mm Hg | 8.7±1.3 | 10.0±1.3 | 10.4±2.2 | 9.2±1.4 |
| CT, ms | 13.4±0.4 | 14.9±0.7 | 14.3±0.8 | 14.6±1.2 |
| RT, ms | 46.1±0.9 | 50.2±0.7† | 43.5±0.8 | 43.2±0.8§ |
| Tau, ms | 7.4±1.2 | 9.1±1.4 | 4.3±1.2 | 4.5±1.5 |
| HR, beats/min | 368±24 | 301±13 | 389±19 | 349±8 |
| LVPmax, mm Hg | 8.7±1.3 | 10.0±1.3 | 10.4±2.2 | 9.2±1.4 |
| CT, ms | 13.4±0.4 | 14.9±0.7 | 14.3±0.8 | 14.6±1.2 |
| RT, ms | 46.1±0.9 | 50.2±0.7† | 43.5±0.8 | 43.2±0.8§ |
| Tau, ms | 7.4±1.2 | 9.1±1.4 | 4.3±1.2 | 4.5±1.5 |
| HR, beats/min | 368±24 | 301±13 | 389±19 | 349±8 |

Data are expressed as mean±SEM. For statistical comparisons 2-way ANOVA followed by Tukey’s multiple comparison test was performed. BPmax indicates maximum systolic blood pressure; CT, contraction time; +dP/dt, maximum rate of left ventricular pressure increase during contraction; −dP/dt, maximum rate of left ventricular decline during relaxation; HR, heart rate; LVEDP, left ventricular end-diastolic pressure; LVPmax, left ventricular maximum systolic pressure; LVPmin, left ventricular minimum diastolic pressure; MK2, mitogen-activated protein kinase–activated protein kinase-2; RT, relaxation time; T, time constant; and TAC, transverse aortic constriction.

*P<0.05 vs MK2+/+.
†P<0.001 vs MK2+/+.
‡P<0.01 vs sham.
§P<0.05 vs sham.
¶P<0.0001 vs sham.
||Indicates a significant interaction between the effects of TAC and genotype; P<0.05.
Ruiz et al Role of MK2 in Cardiac Function

differences were also observed 8 weeks after TAC, they did not reach statistical significance. However, 2-way ANOVA indicated a significant interaction between the effects of TAC and genotype on LV diameter (LV end-diastolic diameter, LV dimension at end cardiac systole), LV mass, and LV function (LV ejection fraction, LV fractional shortening) 2-weeks after TAC (Table 9). Specifically, whereas LV diameter increased and ejection fraction decreased in MK2+/+ mice, the opposite was observed in MK2-deficient mice. Furthermore, a significant interaction between the effects of TAC and genotype on LV ejection fraction and LV fractional shortening was also observed 8 weeks after TAC.

Systolic and early diastolic velocity at the basal segments of the interventricular septum and lateral LV wall was assessed by tissue Doppler imaging. As mentioned above, both lateral and septal systolic tissue velocities were lower in 12-week-old MK2−/− mice relative to MK2+/+ mice (Table 2). Two weeks after TAC, systolic tissue velocities in TAC MK2−/− mice did not differ from those in sham MK2−/− mice (Table 9). In contrast, 2 weeks after TAC, lateral and septal systolic tissue velocities were significantly lower in TAC MK2+/+ relative to sham MK2+/+ mice. However, no differences in systolic tissue velocities were observed 8 weeks after TAC (Table 9). Two-way ANOVA indicated a significant interaction between the effects of TAC and genotype on both systolic and early diastolic tissue velocities (as well as E/E′ and E′/A′), in both septal and lateral segments, 2 weeks after TAC.

Early and late transmitral flow velocities, as well as the E/A ratio, did not differ significantly between TAC MK2+/+ and TAC MK2−/− mice either 2 or 8 weeks after TAC (Table 9). The E wave deceleration time and rate-corrected isovolumetric relaxation time were shortened significantly, relative to sham, in TAC MK2−/− mice but not in TAC MK2+/+ mice 8 weeks after TAC (Figure 9A and 9B). Although these changes suggest LV compliance was reduced in TAC MK2−/− mice, E

**Figure 7. Hypertrophy is delayed in MK2−/− hearts subjected to transverse aortic constriction (TAC).** Pressure overload was induced in MK2−/− and wild-type littermate control (MK+/+) mice by TAC, and mice were euthanized 2 and 8 weeks after surgery. Sham-operated (sham) animals underwent the identical surgical procedure; however, the aorta was not constricted. Left ventricular (LV) maximum developed pressure (LVPmax; A), heart weight–to–tibia length ratio (HW/TL; B), LV mass (C), and left ventricular ejection fraction (LVEF, D). Heart weight refers to the mass of the whole heart (minus atria) as determined gravimetrically. LV mass was determined by echocardiography. Data are expressed as means±SEM. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001 by 2-way ANOVA with Tukey’s multiple-comparison posttest. Number of animals per group are indicated in parentheses. MK2 indicates mitogen-activated protein kinase–activated protein kinase-2.
|                   | Sham MK2+/+ | MK2−/− | TAC MK2+/+ | MK2−/− | Sham MK2+/+ | MK2−/− | TAC MK2+/+ | MK2−/− |
|-------------------|------------|--------|------------|--------|------------|--------|------------|--------|
| **n**             | 17         | 14     | 16         | 15     | 11         | 11     | 11         | 10     |
| **Aortic peak velocity, cm/s** | 70.5±5.3   | 74.8±3.8 | 305±16* | 293±21* | 79.1±4.0   | 72.9±2.7 | 340±11*    | 330±22* |
| **R-R interval, ms** | 151±5      | 184±14  | 148±5      | 157±7  | 150±7      | 173±8  | 137±6      | 146±7  |

**LV structure**

|                   | Sham MK2+/+ | MK2−/− | TAC MK2+/+ | MK2−/− | Sham MK2+/+ | MK2−/− | TAC MK2+/+ | MK2−/− |
|-------------------|------------|--------|------------|--------|------------|--------|------------|--------|
| **LVAWd, mm**     | 0.740±0.012 | 0.743±0.016 | 0.932±0.030 | 0.914±0.039 | 0.725±0.004 | 0.734±0.020 | 0.977±0.046 | 0.997±0.046 | 1.025±0.033* |
| **LVPWd, mm**     | 0.701±0.013 | 0.718±0.020 | 0.870±0.027 | 0.863±0.019 | 0.708±0.009 | 0.736±0.020 | 0.932±0.036 | 0.942±0.025* |
| **LVDp, mm**      | 4.00±0.06   | 4.14±0.07  | 4.18±0.05   | 4.18±0.05  | 4.10±0.05   | 4.08±0.08  | 4.34±0.15   | 4.10±0.05*  |
| **LVDs, mm**      | 2.58±0.09   | 2.76±0.10  | 2.73±0.12   | 2.47±0.10* | 2.75±0.10   | 2.88±0.12  | 3.10±0.23   | 2.66±0.08  |
| **LV mass, mg**   | 103±3      | 112±6    | 151±8*      | 128±7*   | 106±3      | 109±3    | 147±14*     | 164±8*    |
| **LV mass/LVDd, mg/mm** | 38.8±1.6   | 35.8±1.6  | 30.5±1.4    | 29.5±1.4 | 31.2±1.4    | 29.6±1.4 | 29.5±1.4    | 28.5±1.4  |
| **LV mass/BW, mg/g** | 3.78±0.10  | 4.05±0.18 | 5.36±0.29*  | 5.14±0.22* | 3.24±0.18   | 3.06±0.12 | 5.58±0.71*  | 4.88±0.28*  |
| **LV systolic function** |           |         |            |        |            |         |            |        |
| **LVFS, %**       | 33.5±1.3   | 30.5±1.4 | 27.9±1.91 | 37.2±1.11 | 33.2±2.1   | 29.6±1.9 | 29.2±2.8    | 35.1±1.7*  |
| **LVEF, %**       | 68.9±1.8   | 64.4±2.0 | 59.9±3.0†  | 73.6±1.4||,¶* | 67.4±2.8   | 62.9±2.7 | 61.4±4.7    | 70.7±2.1†  |
| **Lateral Sm, cm/s** | 2.17±0.11  | 1.81±0.09 | 1.66±0.07| 1.88±0.15* | 2.00±0.12  | 1.71±0.08 | 1.69±0.11   | 1.59±0.10  |
| **Septal Sm, cm/s** | 2.33±0.11  | 1.85±0.08| 1.88±0.11|| | 1.98±0.13| 2.27±0.11  | 1.87±0.08 | 2.05±0.17   | 1.95±0.06  |

**Transmirtal flow**

|                   | Sham MK2+/+ | MK2−/− | TAC MK2+/+ | MK2−/− | Sham MK2+/+ | MK2−/− | TAC MK2+/+ | MK2−/− |
|-------------------|------------|--------|------------|--------|------------|--------|------------|--------|
| **E velocity, cm/s** | 79.3±1.8   | 78.9±3.1 | 92±3.9* | 91.4±4.5 | 86.0±2.6  | 89.8±3.4 | 104±3†     | 102±6   |
| **E DT, ms**      | 37.9±2.0   | 41.0±1.5 | 34.7±2.0  | 36.2±2.1 | 35.4±1.2  | 37.9±1.3 | 32.6±2.0    | 29.7±1.5*  |
| **ED rate, m/s²** | 21.9±1.1   | 19.6±1.1 | 28.0±2.0  | 26.8±2.5* | 24.7±1.4  | 23.9±1.0 | 32.9±2.2*   | 35.0±2.5²  |
| **A velocity, cm/s** | 45.8±3.5   | 50.4±1.4 | 51.1±6.4  | 51.9±4.7 | 50.8±3.0  | 46.3±3.1 | 49.1±4.0    | 49.2±2.8  |
| **E/A**           | 1.76±0.15  | 1.56±0.07 | 2.01±0.53 | 1.96±0.26 | 1.75±1.0  | 2.34±0.26 | 2.15±0.21   | 2.18±0.23  |
| **Lateral Em, cm/s** | 2.91±0.26  | 2.06±0.18| 2.15±0.24 | 2.50±0.18* | 2.37±0.19 | 2.16±0.16 | 2.71±0.16   | 2.59±0.23  |
| **Lateral Am, cm/s** | 2.53±0.14  | 2.47±0.23 | 2.20±0.36 | 2.04±0.29 | 2.50±0.20 | 1.88±0.08| 2.16±0.15   | 1.78±0.15  |
| **Lateral Em/Am** | 1.13±0.11  | 0.908±0.019 | 0.666±0.018 | 1.52±0.22* | 0.97±0.08 | 1.16±0.08 | 1.31±0.13   | 1.53±0.15  |
| **Lateral E/E m** | 29.2±2.6   | 40.6±4.0  | 45.5±3.8* | 39.0±2.8* | 38.0±3.9  | 43.5±3.6 | 40.0±2.5    | 41.8±3.9  |
| **Septal Em, cm/s** | 3.10±0.29  | 2.19±0.22| 2.38±0.32 | 2.86±0.16* | 2.48±0.15 | 2.50±0.09 | 3.00±0.23   | 2.77±0.17  |
| **Septal Am, cm/s** | 2.71±0.18  | 2.27±0.13 | 2.53±0.57 | 1.95±0.24 | 2.58±0.14 | 2.04±0.09* | 2.27±0.14   | 1.86±0.14  |
| **Septal Em/Am** | 1.06±0.08  | 0.975±0.077 | 0.883±0.110 | 1.71±0.19| 1.00±0.10 | 1.24±0.07 | 1.38±0.17   | 1.57±0.17  |
| **Septal E/E m** | 27.3±2.2   | 38.2±2.9* | 41.4±6.2² | 33.1±2.1* | 35.7±2.4  | 36.5±2.2  | 36.8±3.0    | 37.5±2.5  |

(Continued)
## Table 9. Continued

|                  | 2 wk                  | 8 wk                  |
|------------------|-----------------------|-----------------------|
|                  | Sham                  | TAC                   | Sham                  | TAC                   |
|                  | MK2+/+                | MK2−/−                | MK2+/+                | MK2−/−                | MK2+/+                | MK2−/−                | MK2+/+                | MK2−/−                |
| LV isovolumetric relaxation time |                      |                       |                       |                       |                       |                       |                       |                       |
| IVRT, ms         | 13.3±1.1              | 15.4±1.3              | 13.5±1.2              | 14.3±1.9              | 8.63±0.59             | 11.2±1.1              | 7.26±0.53             | 6.92±1.3*             |
| IVRTC, ms        | 1.08±0.09             | 1.13±0.10             | 1.10±0.09             | 1.08±0.14             | 1.900±0.23            | 2.038±0.065           | 1.625±0.047           | 0.561±0.089*           |
| LADd, mm         | 2.55±0.06             | 2.44±0.04             | 2.79±0.10             | 2.43±0.06‡            | 2.53±0.06             | 2.50±0.05             | 2.86±0.10†            | 2.62±0.07             |
| Pulmonary venous flow |                      |                       |                       |                       |                       |                       |                       |                       |
| Upper S/D        | 0.465±0.043           | 0.534±0.063           | 0.332±0.030           | 0.537±0.106           | 0.635±0.039           | 0.453±0.054           | 0.464±0.046           | 0.515±0.069†           |
| Lower S/D        | 1.79±0.14             | 1.67±0.13             | 2.13±0.21             | 1.70±0.10             | 1.62±0.13             | 1.62±0.14             | 1.98±0.18             | 2.00±0.14             |
| S/D slope        | 5.57±0.35             | 6.53±0.47‡            | 3.93±0.26             | 5.20±0.46§            | 5.48±0.43             | 6.28±0.66             | 4.00±0.13             | 4.45±0.40†             |
| MPI              |                       |                       |                       |                       |                       |                       |                       |                       |
| Septal MPI, %    | 83.9±8.2              | 81.5±5.7              | 96.2±10.1             | 78.7±13.5             | 58.7±2.4              | 60.4±1.9              | 61.7±11.7             | 46.4±2.9              |
| Lateral MPI, %   | 86.9±8.2              | 91.2±8.6              | 99.2±9.9              | 78.5±12.7             | 56.9±1.7              | 58.5±2.5              | 63.1±8.0              | 44.7±3.2†              |
| Global MPI, %    | 54.6±3.0              | 56.5±3.4              | 55.0±5.0              | 38.4±5.1‡             | 40.0±2.2              | 47.8±2.4              | 43.4±8.0              | 33.5±2.1§              |

Data are expressed as mean±SEM. A indicates transmitral flow late (atrial) filling velocity; A\text{m}, mitral annulus peak velocity during atrial diastolic filing; CO, cardiac output; D, peak velocity during pulmonary venous diastolic flow; E, transmitral flow early filling velocity; ED, E wave deceleration; EDT, E wave deceleration time; E\text{m}, mitral annulus peak velocity during early diastolic filing; IVRT, isovolumic relaxation time; IVRTC, heart rate-corrected IVRT; LADd, left atrium dimension at end cardiac diastole; LADs, left atrium dimension at end cardiac systole; LVAXd, left ventricular anterior wall thickness at end cardiac diastole; LVDd, left ventricular dimension at end cardiac diastole; LVDs, left ventricular dimension at end cardiac systole; LVEF, left ventricular ejection fraction; LVPWd, left ventricular posterior wall thickness at end cardiac diastole; LVVd, left ventricular volume at end cardiac diastole; LVVe, left ventricular volume at end cardiac systole; MK2, mitogen-activated protein kinase–activated protein kinase-2; MPI, myocardial performance index; S, peak velocity during pulmonary venous systolic flow; SD slope, pulmonary venous systolic flow decelerating slope; SL, basal lateral systolic velocity; SS, basal septal systolic velocity; and SV, stroke volume.

*P<0.0001 vs sham.
1P<0.01 vs MK2−/−.
2P<0.05 vs MK2−/−.
3P<0.001 vs MK2+/+.
4P<0.05 vs sham.
5Indicates a significant interaction between the effects of TAC and genotype, P<0.05.
6P<0.001 vs sham.
7P<0.01 vs MK2−/−.
8P<0.001 vs MK2+/+.
wave deceleration time and rate-corrected isovolumetric relaxation time in TAC MK2−/− mice did not differ significantly from TAC MK2+/+ mice. In addition, both septal and lateral E/E′ ratios, which reflect LV filling pressure, did not differ. Similarly, the ratio of peak systolic to diastolic pulmonary venous flow velocity, which would increase in response to reduced LV compliance, was similar in TAC MK2+/+ and TAC MK2−/− mice both 2 and 8 weeks after TAC. Furthermore, LA diameter, which may increase in response to a chronic increase in LV filling pressure, increased in TAC MK2+/+ but not TAC MK2−/− mice (Figure 9C). Finally, the myocardial performance index, which increases as cardiac performance is reduced, was reduced in TAC MK2−/− mice relative to both TAC MK2+/+ and sham MK2−/− mice 2 weeks after TAC, although the difference between MK2+/+ and MK2−/− mice no longer reached significance 8 weeks after TAC (Figure 9D). Two-way ANOVA indicated a significant interaction between the effects of TAC and genotype on global myocardial performance index 2-weeks post-TAC and on lateral myocardial performance index 8 weeks after TAC (Table 9). Hence, MK2-deficiency resulted in a delay in hypertrophy and the onset of the changes in LV structure and function evoked by a chronic increase in afterload.

Remodeling of the myocardium in response to a chronic increase in afterload involves both hypertrophy and increased interstitial fibrosis. We previously observed a modest fibrotic effect in mice on the mixed

**FIGURE 8.** MK2 deficiency does not alter the transverse aortic constriction (TAC)-induced increase in fetal gene expression. Pressure overload was induced in MK2−/− and wild-type littermate control (MK2+/+) mice by TAC, and mice were euthanized 2 weeks after surgery. Sham animals underwent the identical surgical procedure; however, the aorta was not constricted. Total RNA was isolated and the abundance of (A) atrial natriuretic peptide (Nnpa) and (B) β-myosin heavy chain (Myh7) mRNA was quantified by quantitative polymerase chain reaction and normalized to Gapdh mRNA levels. Data are expressed as means±SEM. Number of animals per group are indicated in parentheses. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.001 by two-way ANOVA with Tukey’s multiple-comparison posttest. MK2 indicates mitogen-activated protein kinase–activated protein kinase-2.

**DISCUSSION**

Deletion of MK2 in mice had no detrimental impact on survival when examined up to 100 weeks of age. Interestingly, relative to age- and sex-matched littermates, MK2-deficient mice were hypothermic and had significantly lower body weight in later life. At 12 weeks of age, male MK2-deficient mice displayed prolonged R-R intervals as well as signs of early diastolic dysfunction; however, diastolic dysfunction failed to develop with age. The amplitude and decay of calcium transients evoked by either field stimulation or caffeine were similar in ventricular myocytes isolated from adult male MK2+/+ and MK2−/− mice, whereas when perfused ex vivo, in working mode, hearts from MK2−/− mice beat with similar frequency. Acquisition of ECG data in conscious mice by radio telemetry revealed P-R segment prolongation in MK2-deficient mice, suggesting that autonomic regulation of heart function was altered in these mice. Finally, the LV hypertrophy induced by imposing a chronic increase in afterload was delayed but not prevented in MK2-deficient mice.

Echocardiographic imaging in 12-week-old male MK2−/− mice revealed signs of reduced LV compliance, suggesting early diastolic dysfunction. However, MK2-deficient mice failed to develop diastolic dysfunction as they aged. Several factors are known to affect diastolic function, including preload,59 aging,61 and heart rate.62 Although in theory the observed changes in diastolic function in MK2-deficient mice could be related to a decrease in heart rate, isovolumetric relaxation time in 129/Ola x C57BL/6 genetic background.40 Similarly, 8 weeks after TAC, Masson’s trichrome staining revealed very little increased interstitial fibrosis in TAC MK2+/+ and TAC MK2−/− mice relative to their respective sham controls (Figure 10).

TAC activates the p38 pathway, with a peak activation occurring 3 days after TAC.12,55 Furthermore, pharmacologic inhibition of p38α/β potentiates ERK1/2 activation in cardiac myocytes.51 Hence, we examined the effects of MK2-deficiency and TAC on phosphorylation of p38, MEK1/2, and ERK1/2 within their activation loops. Two weeks after TAC, ERK1/2, MEK1/2 and p38 phosphorylation (normalized to total immunoreactivity) in TAC and sham hearts did not differ significantly. In each case, a modest but not significant reduction in phosphorylation was observed in the samples from MK2-deficient hearts (data not shown). In addition, MK2 deficiency has been shown previously to destabilize p38α leading to a reduction p38α immunoreactivity.33,59 The abundance of p38α immunoreactivity was reduced in MK2-deficient hearts to a similar extent in sham and TAC hearts 2 weeks after TAC (data not shown).
MK2−/− mice was significantly longer than MK2+/+ mice even after being corrected for heart rate. Among clinical strategies used to improve diastolic function, treatments such as beta blockers have been employed to both decrease heart rate and increase diastolic filling time.63 Hence, one possible explanation for the lack of progression to diastolic dysfunction in MK2−/− mice could be a protective effect resulting from reduced heart rate. 64 Consistent with this, when ECGs were acquired from conscious mice using radio telemetry, prolonged R-R intervals were observed in MK2-deficient mice along with prolongation of the P-R segment with no change in the P wave–to–QRS complex ratio. These observations are also consistent with there being alterations in autonomic regulation of heart function in the MK2-deficient mice. However, this hypothesis is based on basic functional observations, and further investigations will be required to better understand the role of MK2 in parasympathetic and sympathetic regulation of cardiac function, including the conduction velocity within the atrioventricular node, and the G protein–coupled receptors involved in the catecholaminergic control of heart rate and contractility.65 Overall, the above-mentioned results suggest a novel role for MK2 in regulating heart rate and diastolic function and highlight a new putative therapeutic target for

Figure 9. MK2-deficient hearts are not predisposed to further diastolic dysfunction when challenged with a chronic increase in afterload.
Pressure overload was induced in MK2−/− and wild-type littermate control (MK+/+) mice by constriction of the transverse aorta (TAC), and mice were euthanized 2 and 8 weeks after surgery. Sham-operated (sham) animals underwent the identical surgical procedure; however, the aorta was not constricted. A, E wave deceleration time (EDT), B, isovolumetric relaxation time corrected for differences in R-R interval (IVRTc), C, left atrial diameter at systole (LAD), and D, global myocardial performance index (MPI: note that higher values indicate poorer cardiac function). Data are presented as means±SEM. *P<0.05, **P<0.01 by two-way ANOVA with Tukey’s multiple-comparison posttest. Number of animals per group are indicated in parentheses. MK2 indicates mitogen-activated protein kinase–activated protein kinase-2.
Ruiz et al Role of MK2 in Cardiac Function

Similarly, we recently reported that a deficiency in MK2 protects mice against diabetes mellitus–induced cardiac diastolic dysfunction.33 Mitochondria play a central role in cardiac energy production and transduction since mitochondrial oxidative phosphorylation is responsible for roughly 90% of the ATP production in the cardiomyocyte. A close link between mitochondrial failure and cardiac remodeling and dysfunction has been illustrated in various genetic models, particularly in mouse models lacking transcriptional coactivators and key drivers of mitochondrial biogenesis and function,66 such as PGC-1α,67 PGC-1β,68 or both.69 A similar link has been established in mouse70 and in rat71 models of heart failure as well as in the human failing heart following ischemic heart disease or dilated cardiomyopathy.72 In fact, heart failure is characterized by alterations in energy metabolism that include changes in substrate use for energy production, particularly depressed fatty acid use, as well as changes in the expression of molecular regulators involved in the PGC-1α/peroxisome proliferator-activated receptor-α axis.73,74 Therefore, targeting mitochondria in heart diseases, especially heart failure, through induction of modulators of mitochondrial biogenesis, for example, remains an active field of research aimed at identifying new therapeutic strategies.75 In MK2-deficient mice, despite no significant changes in mitochondrial respiration rates and the activity of mitochondrial enzymes, other than succinate dehydrogenase, we observed an intriguing increase in the expression of key metabolic genes including PGC-1α and genes involved in fatty acid metabolism. MK2 has been shown to regulate the stability of mRNAs containing adenylate-uridylate–rich elements,30,76 which could explain at least part of the changes. Based on the role of depressed PGC-1α and fatty acid–related metabolic genes in mitochondrial dysfunction in heart failure, the fact that MK2-deficient mice exhibited enhanced expression of these latter genes and improved diastolic function, suggest that MK2 could be considered as an attractive target to improve mitochondrial function in heart diseases. Similar alterations in gene expression have been observed in skeletal muscle from mice where both MK2 and MAPK-activated protein kinase-3 have been deleted.77 However, the implication of uncoupling protein in heart failure is more controversial.78,79 Our results on uncoupling protein expression, including uncoupling protein 3, which was increased in MK2-deficient mice, are more conflicting since some evidence supports a maladaptive effect of uncoupling proteins as key uncouplers of mitochondrial oxidative phosphorylation that decrease energetic efficiency80 while other studies pointed to an adaptive phenomenon of uncoupling proteins in response to lipid accumulation as exporters of fatty acids81 and by their ability to prevent reactive oxygen species accumulation and cardiomyocyte apoptosis.78 Therefore, the significance of our findings needs to be further clarified and the metabolic profile of MK2-deficient hearts under conditions of stress assessed.

Among mechanisms involved in mitochondrial pathogenesis is the opening of the mPTP.82,83 The exact molecular identity of this complex has not yet been well defined and is the subject of intense debate, although the molecular structure of mPTP includes the voltage-dependent anion channel, the adenine nucleotide translocator, and cyclophilin D, among other possible components that include the F1F0 ATP synthase for the pore-forming component.82,84 Nevertheless, increased or sustained mPTP opening subsequent to reactive oxygen species or Ca2+ overload is involved in mitochondrial membrane permeabilization, which in turn results in mitochondrial respiratory chain uncoupling.

heart diseases involving LV diastolic dysfunction. Similarly, we recently reported that a deficiency in MK2 protects mice against diabetes mellitus–induced cardiac diastolic dysfunction.33

Mitochondria play a central role in cardiac energy production and transduction since mitochondrial oxidative phosphorylation is responsible for roughly 90% of the ATP production in the cardiomyocyte. A close link between mitochondrial failure and cardiac remodeling and dysfunction has been illustrated in various genetic models, particularly in mouse models lacking transcriptional coactivators and key drivers of mitochondrial biogenesis and function,66 such as PGC-1α,67 PGC-1β,68 or both.69 A similar link has been established in mouse70 and in rat71 models of heart failure as well as in the human failing heart following ischemic heart disease or dilated cardiomyopathy.72 In fact, heart failure is characterized by alterations in energy metabolism that include changes in substrate use for energy production, particularly depressed fatty acid use, as well as changes in the expression of molecular regulators involved in the PGC-1α/peroxisome proliferator-activated receptor-α axis.73,74 Therefore, targeting mitochondria in heart diseases, especially heart failure, through induction of modulators of mitochondrial biogenesis, for example, remains an active field of research aimed at identifying new therapeutic strategies.75 In MK2-deficient mice, despite no significant changes in mitochondrial respiration rates and the activity of mitochondrial enzymes, other than succinate dehydrogenase, we observed an intriguing increase in the expression of key metabolic genes including PGC-1α and genes involved in fatty acid metabolism. MK2 has been shown to regulate the stability of mRNAs containing adenylate-uridylate–rich elements,30,76 which could explain at least part of the changes. Based on the role of depressed PGC-1α and fatty acid–related metabolic genes in mitochondrial dysfunction in heart failure, the fact that MK2-deficient mice exhibited enhanced expression of these latter genes and improved diastolic function, suggest that MK2 could be considered as an attractive target to improve mitochondrial function in heart diseases. Similar alterations in gene expression have been observed in skeletal muscle from mice where both MK2 and MAPK-activated protein kinase-3 have been deleted.77 However, the implication of uncoupling protein in heart failure is more controversial.78,79 Our results on uncoupling protein expression, including uncoupling protein 3, which was increased in MK2-deficient mice, are more conflicting since some evidence supports a maladaptive effect of uncoupling proteins as key uncouplers of mitochondrial oxidative phosphorylation that decrease energetic efficiency80 while other studies pointed to an adaptive phenomenon of uncoupling proteins in response to lipid accumulation as exporters of fatty acids81 and by their ability to prevent reactive oxygen species accumulation and cardiomyocyte apoptosis.78 Therefore, the significance of our findings needs to be further clarified and the metabolic profile of MK2-deficient hearts under conditions of stress assessed.

Among mechanisms involved in mitochondrial pathogenesis is the opening of the mPTP.82,83 The exact molecular identity of this complex has not yet been well defined and is the subject of intense debate, although the molecular structure of mPTP includes the voltage-dependent anion channel, the adenine nucleotide translocator, and cyclophilin D, among other possible components that include the F1F0 ATP synthase for the pore-forming component.82,84 Nevertheless, increased or sustained mPTP opening subsequent to reactive oxygen species or Ca2+ overload is involved in mitochondrial membrane permeabilization, which in turn results in mitochondrial respiratory chain uncoupling.

Figure 10. MK2 deficiency had no effect on interstitial fibrosis.
A, Transverse cryosections (8 mm) of the ventricular myocardium were stained with Masson’s trichrome 8 weeks after TAC. B, collagen content was quantified by color segmentation. The original magnification was ×40. Data are expressed as means±SEM. Number of animals per group are indicated in parentheses. MK2 indicates mitogen-activated protein kinase–activated protein kinase-2; and TAC, transverse aortic constriction.
as well as impaired oxidative phosphorylation, blunted ATP production, and ultimately mitochondrial swelling and cell death.83,85 There is increasing evidence supporting a role for mPTP opening in cardiac diseases. In ischemia-reperfusion injury, prolonged mPTP opening has been described as a key contributor to postischemia/reperfusion-mediated cardiomyocyte death.86 Similarly, in response to volume overload, mitochondrial vulnerability to mPTP opening increased during compensated ventricular hypertrophy.87,88 In rats subjected to coronary artery ligation, mPTP opening was prolonged during myocardial infarction.89 Finally, mPTP opening appears to persist in failing hearts following chronic pacing or postinfarction remodeling in dogs90 as well as in rats following decompensated hypertrophy secondary to TAC-induced increased afterload.91 Therefore, targeting mPTP opening is now considered to be a promising therapeutic target for the treatment of cardiac diseases and new strategies aimed at limiting mPTP opening are required to overcome the existing challenges that limit the development of specific mPTP inhibitors.84,92 Our results show that inhibiting MK2 signaling reduced the Ca2+ sensitivity for mPTP opening; hence, MK2 or its downstream targets may warrant consideration in the development novel cardioprotective therapies.

When the effects of a chronic increase in afterload on cardiac remodeling were examined in MK2-deficient mice, the findings were consistent with those of Streicher et al.21 By inducing the overexpression of a constitutively-active form of MKK3 (MKK3E) in a cardiomyocyte-specific manner, these authors showed that MK2 participates in the p38-mediated pathological cardiac remodeling and contractile dysfunction. In addition, a deficiency of MK2 attenuates ventricular hypertrophy and improves contractility, despite no difference in the expression molecular markers of remodeling. Similarly, our results show that following TAC, MK2-deficient mice took longer to develop significant levels of hypertrophy while showing improved contractility, despite no difference in the expression of hypertrophic markers. More specifically, 2-weeks after TAC, MK2-deficient mice showed improved (1) LV systolic function as well as (2) LV diastolic properties. These findings do not entirely concur with the findings of Streicher et al, who further showed that knocking out MK2 in MKK3E-overexpressing hearts does not rescue myocardial stiffness.21 This discrepancy can be explained by the different model used: chronic activation of p38 MAPK versus TAC-induced increased afterload. Being a downstream target of p38α/β, MK2 could be contributing to the pathogenic responses of p38 activation by either modulating total p38α protein levels or mediated downstream signaling. In fact, in MK2-deficient mice, the amount of p38α is significantly reduced,33 since MK2 stabilizes p38α via a direct interaction with its C-terminal.59 Alternatively, downstream targets of MK2, such as hsp25/27, may mediate molecular events induced by MK2 activation. Overexpression of a nonphosphorylatable hsp27 mutant improves cardiac performance.93 However, it is noteworthy that the benefits of MK2 loss observed 2 weeks after TAC were less pronounced when examined 8 weeks after TAC, albeit hearts from MK2−/− mice after 8-week TAC showed a better compliance. These differences suggest that rather than abrogating pressure overload–induced contractile dysfunction, the absence of MK2 delays the pathogenic response. MK5 is a putative target of p38α/β as well as atypical MAP kinases ERK3 and ERK4 that is also expressed in heart cells.94,95 In contrast to the effects shown herein for MK2 deficiency, MK5 haplodeficiency results in a significant attenuation of LV hypertrophy 8 weeks after TAC.40 The downstream effectors of MK2 and MK5 in cardiac cells and their roles in pathological remodeling of the myocardium remain to be determined.

Potential Limitations

One limitation of the present study is the animal model. The MK2-deficient mice are pan knockouts rather than cardiomyocyte specific. Hence, the involvement of body temperature, peripheral mechanisms, or systemic mediators in the observed cardiac phenotype cannot be excluded. In addition, although the overall aim of this study was to perform a comprehensive analysis of the role of MK2 in regulating basal cardiac function and its implication in pathological remodeling, our results do not shed light on the molecular mechanisms by which MK2 regulates cardiac function in health and disease, thereby representing another limitation. Further studies using cell type–specific MK2-deficient models will be required.

CONCLUSIONS

MK2-deficient mice showed no adverse effects on myocardial performance over time. Interestingly, autonomic regulation of cardiac function appears to be altered in the absence of MK2. In addition, MK2-deficient mice showed changes in the expression of some metabolic genes related to mitochondrial biogenesis and fatty acid metabolism, despite no alterations in mitochondrial respiration rates. Furthermore, the calcium-sensitivity for mPTP opening was reduced, suggesting a cardioprotective effect of MK2 loss. Finally, in response to a chronic increase in afterload, LV hypertrophy was delayed but not reduced or prevented. Altogether these findings support a novel role for MK2 in the heart that merits
further investigation, especially in regard to its possible role in autonomic regulation of heart function, the regulation of metabolic gene expression, and mPTP opening as these may represent interesting cardioprotective roles for inhibitors of MK2. In addition, consistent with previous work using a constitutive form of MK2 deficiency, we confirm that MK2 is implicated in the pathological processes leading to cardiac hypertrophy and ventricular dysfunction.

ARTICLE INFORMATION
Received June 1, 2020; accepted November 9, 2020.
Additional information: Coauthor William C. Stanley, PhD, died October 21, 2013.

Affiliations
From the Department of Medicine (M.R., J.-C.T., B.G.A.), Department of Biochemistry and Molecular Medicine (M.K., D.D., G.V., J.T., P.S., B.G.A.), Department of Pharmacology and Physiology (S.A.N., A.N., M.G.S., B.G.A.), and Faculté de Pharmacie (S.T., C.F.), Université de Montréal, Montréal, Québec, Canada; Montreal Heart Institute, Montréal, Québec, Canada (M.R., M.K., D.D., G.V., J.T., Y.S., A.D., B.H., S.A.N., P.S., A.N., F.S., M.-A.G., M.G.S., C.F., J.-C.T., B.G.A.); University of Maryland, Baltimore, MD (F.I.K., W.C.S.); L’Institut du Thorax, INSERM, CNRS, Université de Nantes, France (B.L.); Institute of Cell Biochemistry, Hannover Medical School, Hannover, Germany (M.G.); and Department of Physiology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt (S.A.N.).

Acknowledgments
We thank Ms Karine Bouthillier and Dr Robert Parent for animal care and breeding as well as Dr Christine Des Rosiers for her thoughtful comments. Author contributions: Drs Ruiz, Khairallah, Dingar, Vaniotis, Trépanier, Khairallah, Shi, Hussein, Nguyen, and Allen conceived and designed the experiments. Drs Ruiz, Khairallah, Dingar, Vaniotis, Trépanier, Khairallah, Shi, Hussein, Nguyen, Nawato, Sahmi, and Sahadevan performed the experiments and analyzed the data. Drs Ruiz, Khairallah, and Allen assembled and interpreted all the data. Dr Gaestel provided the mouse model. Drs Ruiz, Khairallah, and Allen wrote and critically reviewed the manuscript. All authors have approved the final version of the current manuscript.

Sources of Funding
This work is supported by grants from the Canadian Institutes of Health Research (MOP-77791), the Heart and Stroke Foundation of Canada (Grant Numbers G-14-0006060 and G-18-0022227), and the Montreal Heart Institute Foundation to Dr Allen. Dr Tardif holds the Canada Research Chair in translational and personalized medicine and the Université de Montréal-Pére endowed research chair in atherosclerosis.

Disclosures
None.

REFERENCES
1. Frey N, Katzis HA, Olsen EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109:1580–1589. DOI:10.1161/01.CIR.0000120390.68287.BB.
2. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med. 1998;4:1269–1275. DOI:10.1016/S0888-7543(98)00263-9.
3. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 2014;71:549–574. DOI:10.1007/s00018-013-1349-6.
4. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551–571. DOI:10.1146/annurev.physiol.59.1.551.
5. Frey N, Luedde M, Katus HA. Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol. 2011;9:91–100. DOI:10.1038/nrcardio.2011.159.
6. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet. 2011;378:704–712. DOI:10.1016/S0140-6736(11)60894-5.
7. Trempe N, Dave-Col N, Nebreda AR, SnappGhost. p38 MAPK signaling. Cell. 2013;152:656–656.e1. DOI:10.1016/j.cell.2013.01.029.
8. Arabacilar P, Marber M. The case for inhibiting p38 mitogen-activated protein kinase in heart failure. Front Pharmacol. 2015;6:102. DOI:10.3389/fphar.2015.00102.
9. Bellahcene M, Jacquet S, Cao XB, Tanno M, Haworth RS, Layland J, Kabir AM, Gaestel M, Davis RJ, Fallavolta RA, et al. Activation of p38 mitogen-activated protein kinase contributes to the early cardiodepressant action of tumor necrosis factor. J Am Coll Cardiol. 2006;48:545–555. DOI:10.1016/j.jacc.2006.02.072.
10. Chahine MN, Mioulane M, Sikkel MB, O’Gara P, Dos Remedios CG, Pierce GN, Lyon AR, Folds G, Harding SE. Nuclear pore rearrangements and nuclear trafficking in cardiomyocytes from rat and human failing hearts. Cardiovasc Res. 2015;105:31–43. DOI:10.1093/cvr/cvu218.
11. Takeishi Y, Huang Q, Abe J, Che W, Lee JD, Kawakatsu H, Hoit BD, Berk BC, Walsh RA. Activation of mitogen-activated protein kinases and p90 ribosomal S6 kinase in failing human hearts with dilated cardiomyopathy. Cardiovasc Res. 2002;53:131–137. DOI:10.1016/S0008-6363(01)00438-2.
12. Dingar D, Merlen C, Grandy S, Gillis MA, Villeneuve LR, Mammarachi AM, Fiset C, Allen BG. Effect of pressure overload-induced hypertrophy on the expression and localization of p38 MAP kinase isoforms in the mouse heart. Cell Signal. 2010;22:1634–1644. DOI:10.1016/j.cellsig.2010.06.002.
13. Lemke LE, Bloem LJ, Fouts R, Esterman M, Sandusky G, Vlahos CJ. Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK is the predominant isoform expressed in human heart. J Mol Cell Cardiol. 2001;33:1527–1540.
14. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem. 1998;273:2161–2168.
15. Yokota T, Wang Y, p38 MAP kinases in the heart. Gene. 2016;575:369–376. DOI:10.1016/j.gene.2015.06.030.
16. Gonzalez-Teran B, Lopez JA, Rodriguez E, Leiva L, Martinez-Martinez S, Bernal JA, Jimenez-Borreguero JL, Redondo JM, Vazquez J, Sabio G. p38δ and 5 promote heart hypertrophy by targeting the mTOR-inhibitory protein DEPTOR for degradation. Nat Commun. 2016;7:10477. DOI:10.1038/ncomms10477.
17. Nemoto S, Sheng Z, Lin A. Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiac hypertrophy, Mol Cell Biol. 1998;18:3518–3526.
18. Braz JC, Bueno OF, Liang Q, Wilkins BJ, Dai Y-S, Parsons S, Braunwart J, Glasscock BJ, Klevitsky R, Kimball TF, et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling. J Clin Invest. 2003;111:1475–1486. DOI:10.1172/JCI100296.
19. Zhang S, Weinheimer C, Courtois M, Kovaca A, Zhang CE, Cheng AM, Wang Y, Muslin AJ. The role of the Grib2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest. 2003;111:833–841. DOI:10.1172/JCI16290.
20. Nashida K, Yamaguchi O, Hirotsu S, Hikoso S, Higuchi Y, Watanabe T, Takeda O, Tsuda S, Morita T, Kondoh G, et al. p38α mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol Cell Biol. 2004;24:10611–10620.
21. Streicher JM, Ren S, Hershman H, Wang Y. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart. Circ Res. 2010;106:1434–1443.
22. Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microb Mol Biol Rev. 2011;75:75–80. DOI:10.1128/MMBR.00031-10.
23. Coulllard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38MAPK stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009;15:369–379. DOI:10.1016/j.molmed.2009.06.005.
24. Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway—a potential target for intervention in infarction, hypertrophy,
and heart failure. J Mol Cell Cardiol. 2011;51:485–490. DOI:10.1016/j.yjmcc.2010.10.021.

25. Martin ED, Bassi R, Marber MS. p38 MAPK in cardioprotection—are we there yet? Br J Pharmacol. 2015;172:2101–2113. DOI:10.1111/bjp.12901.

26. Fiore M, Forli S, Manetti F. Targeting mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2); medicinal chemistry efforts to lead small molecule inhibitors to clinical trials. J Med Chem. 2016;59:3609–3634. DOI:10.1021/acs.jmedchem.6b01457.

27. Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679–692. DOI:10.1038/nri3495.

28. Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38. EMBO J. 2003;22:5793–5806. DOI:10.1038/sj.emboj.7601522.

29. Dulos J, Wijnands FP, van den Hurk-van Abeek JA, van Vugt MJG, Ruullmann JA, Schot JJ, de Groot MW, Wagenaaars JL, van Ravestein-van OR, Smets RL, et al. p38 inhibition and not MK2 inhibition enhances the secretion of chemokines from TNF-α-activated rheumatoid arthritis fibroblast-like synoviocytes. Clin Exp Rheumatol. 2013;31:515–525.

30. Ruiz M, Codere L, Allen BG, Des RC. Protecting the heart through MK2 modulation, toward a role in diabetic cardiomyopathy and lipid metabolism. Biochim Biophys Acta. 2018;1884:1914–1922. DOI:10.1016/j.bbadis.2017.07.015.

31. Shirito K, Otani H, Yamamoto F, Huang CK, Maulik N, Das DK. MK2 kinase knock-out mouse hearts carry anti-apoptotic signal and are resistant to ischemia reperfusion injury. J Mol Cell Cardiol. 2005;38:93–97.

32. Xu L, Yates CC, Lockyer P, Xie L, Beviacqua A, He J, Lander C, Patterson C, Williams MM. Mmp-10100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition. J Mol Cell Cardiol. 2014;74:866–861. DOI:10.1016/j.yjmcc.2014.09.011.

33. Ruiz M, Codere L, Lachance D, Houde V, Martel C, Thompson Legault W, Brand G, Brodeur MR, Charpentier D, Rhainds D, et al. HDL lipidation decreases collagen deposition and scar size during post-myocardial infarction wound repair. Am J Physiol Heart Circ Physiol. 2017;313:H46–H58. DOI:10.1152/ajpheart.00597.2016.

34. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HJ. Alternative translation initiation generates a functionally distinct isoform of the stress-activated protein kinase MK2. Cell Rep. 2019;27:2850–2870.e2856. DOI:10.1016/j.celrep.2019.05.014.

35. Duda O., O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, Chess DJ, Azimadheem AZ, Harris WS, Sharov VG, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res. 2009;81:319–327. DOI:10.1093/cvr/cvq0310.

36. Connern CP, Halesrap PH. Chaotropic agents and increased matrix volume enhance binding of mitochondrial cyclophilin to the inner mitochondrial membrane and sensitize the mitochondrial permeability transition to [Ca2+]o. Biochemistry. 1996;35:8172–8180.

37. Trolle P, Snieckute G, Bekker-Jensen D, Menon MB, Freund R, Kotlyarov A, Olsen JV, Diaz-Muñoz MD, Turner M, Bekker-Jensen S, et al. Alternative translation initiation generates a functionally distinct isoform of the stress-activated protein kinase MK2. Cell Rep. 2019;27:2850–2870.e2856. DOI:10.1016/j.celrep.2019.05.024.

38. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J. 1984;107:526–531. DOI:10.1016/S0002-7816(84)90095-4.

39. Constantinescu C, Murphy K. Molecular and integrative physiological effects of isoflavone administration: the paradigm of cardiovascular studies in rodents using magnetic resonance imaging. Front Cardiovasc Med. 2016;3:23. DOI:10.3389/fcm.2016.00023.

40. Verwey NJ, Mateo Leach I, van den Boogaard M, van Veldhuisen DJ, Christofilos VM; LifeLines Cohort S, Hillege HL, van Gilst WH, Barnett P, Boon EN; LIFEPlus Investigators. Alterations in carbohydrate metabolism and its regulation in normal and hypertrophied myocardium. Circulation. 2010;121:987–999. DOI:10.1161/CIRCULATIONAHA.113.016889.
